Guided Therapeutics (GTHP) 10-Q 15 Nov 21 2021 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2021	Nov. 10, 2021
Cover [Abstract]
Entity Registrant Name	GUIDED THERAPEUTICS, INC.
Entity Central Index Key	0000924515
Document Type	10-Q
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Current Reporting Status	Yes
Document Period End Date	Sep. 30, 2021
Entity Filer Category	Non-accelerated Filer
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2021
Entity Common Stock Shares Outstanding		13,633,583
Document Quarterly Report	true
Document Transition Report	false
Entity Interactive Data Current	Yes
Entity File Number	0-22179
Entity Incorporation State Country Code	DE
Entity Tax Identification Number	58-2029543
Entity Address Address Line 1	5835 Peachtree Corners East
Entity Address Address Line 2	Suite B
Entity Address City Or Town	Norcross
Entity Address State Or Province	GA
Entity Address Postal Zip Code	30092
City Area Code	770
Local Phone Number	242-8723

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Current Assets:
Cash and cash equivalents	$ 541,000	$ 182,000
Accounts receivable, net of allowance for doubtful accounts of $126 at September 30, 2021 and December 31, 2020	24,000	24,000
Inventory, net of reserves of $785 and $758 at September 30, 2021 and December 31, 2020, respectively	590,000	605,000
Other current assets	173,000	85,000
Total current assets	1,328,000	896,000
Non-Current Assets:
Property and equipment, net	11,000	1,000
Operating lease right-of-use assets, net of amortization	388,000	453,000
Other assets	17,000	0
Total non-current assets	416,000	454,000
TOTAL ASSETS	1,744,000	1,350,000
Current Liabilities:
Accounts payable	2,220,000	2,419,000
Accounts payable, related parties	94,000	116,000
Accrued iabilities	1,380,000	2,995,000
Deferred revenue	278,000	42,000
Current portion of lease liability	64,000	56,000
Current portion of long-term debt	18,000	28,000
Notes payable in default	0	328,000
Notes payable in default, related parties	0	1,000
Short-term notes payable	83,000	45,000
Short-term notes payable, related parties	50,000	51,000
Convertible notes payable, past due	0	1,930,000
Short-term convertible notes payable	728,000	951,000
Total current liabilities	5,076,000	8,962,000
Long-Term Liabilities
Warrants, at fair value	0	2,203,000
Long-term lease Liabilities	343,000	392,000
Derivative liability	30,000	25,000
Long-term convertible debt	787,000	23,000
Long-term debt, related parties	586,000	600,000
Total long-term liabilities	1,746,000	3,243,000
Total liabilities	6,822,000	12,205,000
STOCKHOLDERS' DEFICIT:
Common stock, $.001 par value; 3,000,000 shares authorized, 13,607 and 13,138 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively	3,403,000	3,403,000
Additional paid-in capital	126,650,000	123,109,000
Treasury stock at cost	(132,000)	(132,000)
Accumulated deficit	(141,878,000)	(139,956,000)
Total stockholders' deficit	(5,078,000)	(10,855,000)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	1,744,000	1,350,000
Series C Convertible Preferred Shares
STOCKHOLDERS' DEFICIT:
Preferred Stock Value	105,000	105,000
Series C1 Convertible Preferred Shares
STOCKHOLDERS' DEFICIT:
Preferred Stock Value	170,000	170,000
Series C2 Convertible Preferred Shares
STOCKHOLDERS' DEFICIT:
Preferred Stock Value	531,000	531,000
Series D Convertible Preferred Shares
STOCKHOLDERS' DEFICIT:
Preferred Stock Value	276,000	276,000
Series E Convertible Preferred Shares
STOCKHOLDERS' DEFICIT:
Preferred Stock Value	1,639,000	1,639,000
Series F Convertible Preferred Shares
STOCKHOLDERS' DEFICIT:
Preferred Stock Value	1,195,000	0
Series F-2 Convertible Preferred Shares
STOCKHOLDERS' DEFICIT:
Preferred Stock Value	2,963,000	0
Series G Convertible Preferred Shares
STOCKHOLDERS' DEFICIT:
Preferred Stock Value	$ 0	$ 0

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
CURRENT ASSETS:
Accounts receivable, net of allowance	$ 126,000	$ 126,000
Inventory, net of reserves	$ 785,000	$ 758,000
STOCKHOLDERS' DEFICIT:
Common stock, par value	$ 0.001	$ 0.001
Common stock, authorized	3,000,000,000	3,000,000,000
Common stock, issued	13,138,000	13,138,000
Common stock, outstanding	13,607,000	13,138,000
Preferred stock, par value	$ 0.001
Preferred stock, authorized	5,000,000
Series C Convertible Preferred Shares
STOCKHOLDERS' DEFICIT:
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, authorized	9,000	9,000
Preferred stock, liquidation preference	$ 286,000	$ 286,000
Preferred stock, issued	300	300
Preferred stock, outstanding	300	300
Series D Convertible Preferred Shares
STOCKHOLDERS' DEFICIT:
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, authorized	6,000	6,000
Preferred stock, liquidation preference	$ 763,000	$ 763,000
Preferred stock, issued	800	800
Preferred stock, outstanding	800	800
Series E Convertible Preferred Shares
STOCKHOLDERS' DEFICIT:
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, authorized	5,000	5,000
Preferred stock, liquidation preference	$ 1,736,000	$ 1,736,000
Preferred stock, issued	1,700	1,700
Preferred stock, outstanding	1,700	1,700
Series F Convertible Preferred Shares
STOCKHOLDERS' DEFICIT:
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, authorized	1,500	1,500
Preferred stock, liquidation preference	$ 1,436,000	$ 1,436,000
Preferred stock, issued	1,400	0
Preferred stock, outstanding	1,400	0
Series F-2 Convertible Preferred Shares
STOCKHOLDERS' DEFICIT:
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, authorized	5,000	5,000
Preferred stock, liquidation preference	$ 3,339,000	$ 3,339,000
Preferred stock, issued	3,300	0
Preferred stock, outstanding	3,300	0
Series G Convertible Preferred Shares
STOCKHOLDERS' DEFICIT:
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, authorized	1,000,000	1,000,000
Preferred stock, liquidation preference	$ 0	$ 0
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
Series C-1 Convertible Preferred Shares
STOCKHOLDERS' DEFICIT:
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, authorized	20,300	20,300
Preferred stock, liquidation preference	$ 1,049,000	$ 1,049,000
Preferred stock, issued	1,000	1,000
Preferred stock, outstanding	1,000	1,000
Series C-2 Convertible Preferred Shares
STOCKHOLDERS' DEFICIT:
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, authorized	5,000,000	5,000,000
Preferred stock, liquidation preference	$ 3,263,000	$ 3,263,000
Preferred stock, issued	3,300	3,300
Preferred stock, outstanding	3,300	3,300

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)
Sales - devices and disposables	$ 19,000	$ 77,000	$ 21,000	$ 77,000
Cost of goods sold	42,000	12,000	42,000	19,000
Gross profit (loss)	(23,000)	65,000	(21,000)	58,000
Operating expenses:
Research and development	16,000	41,000	52,000	121,000
Sales and marketing	41,000	36,000	107,000	107,000
General and administrative	407,000	141,000	1,747,000	593,000
Total operating expenses	464,000	218,000	1,906,000	821,000
Loss from operations	(487,000)	(153,000)	(1,927,000)	(764,000)
Other income (expenses):
Interest expense	(594,000)	(317,000)	(1,050,000)	(910,000)
Change in fair value of derivative liability	(1,000)	(36,000)	(89,000)	(36,000)
Gain (loss) from extinguishment of debt	763,000	20,000	578,000	(296,000)
Change in fair value of warrants	0	2,061,000	448,000	(490,000)
Other income/loss	387,000		414,000	51,000
Total other income (expense)	555,000	1,728,000	301,000	(1,681,000)
Net income (loss)	68,000	1,575,000	(1,626,000)	(2,445,000)
Preferred stock dividends	(119,000)	(46,000)	(296,000)	75,000
NET INCOME (LOSS) ATTRIBUTABLE TO COMMON STOCKHOLDERS	$ (51,000)	$ 1,529,000	$ (1,922,000)	$ (2,520,000)
NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS
Basic	$ 0	$ 0.12	$ (0.14)	$ (0.25)
Diluted	$ 0	$ 0.03	$ (0.14)	$ (0.25)
Weighted average shares outstanding
Weighted average shares outstanding Basic	13,417	12,995	13,291	9,985
Weighted average shares outstanding Diluted	13,417	60,331	13,291	9,985

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT - USD ($)	Total	Preferred Stock Series C [Member]	Preferred Stock Series C1 [Member]	Preferred Stock Series C2 [Member]	Preferred Stock Series D [Member]	Preferred Stock Series E [Member]	Common Stock [Member]	Additional Paid-In Capital	Treasury Stock [Member]	Accumulated Deficit [Member]	Preferred Stock Series F [Member]	Preferred Stock Series F-2 [Member]	Preferred Stock Series G [Member]
Balance, shares at Dec. 31, 2019			1,000	3,000			3,319,000
Balance, amount at Dec. 31, 2019	$ (16,935,000)	$ 105,000	$ 170,000	$ 531,000	$ 0	$ 0	$ 3,394,000	$ 118,552,000	$ (132,000)	$ (139,555,000)
Issuance of preferred stock in financing, shares					1,000	2,000
Issuance of preferred stock in financing, amount	1,815,000				$ 276,000	$ 1,539,000
Conversion of debt into common stock, shares							8,132,000
Conversion of debt into common stock, amount	2,929,000						$ 8,000	2,921,000
Issuance of common stock in financing, shares							1,526,000
Issuance of common stock in financing, amount	462,000						$ 2,000	460,000
Issuance of warrants in financing amount	70,000							70,000
Issuance of common stock for manufacturing agreements, shares							12,000
Issuance of common stock for payment of Series D preferred dividends, shares					107,000		107,000
Issuance of common stock for payment of Series D preferred dividends, amount	26,000				$ 0		$ 0	26,000
Beneficial conversion feature of debt amount	82,000							82,000
Stock based compensation	251,000							251,000
Accrued series D preferred stock dividends	(75,000)									(75,000)
Net Income	(2,445,000)									(2,445,000)
Balance, shares at Sep. 30, 2020			1,000	3,000	108,000	2,000	13,096,000
Balance, amount at Sep. 30, 2020	(13,820,000)	105,000	$ 170,000	$ 531,000	$ 276,000	$ 1,539,000	$ 3,404,000	122,362,000	(132,000)	(142,075,000)
Balance, shares at Dec. 31, 2019			1,000	3,000			3,319,000
Balance, amount at Dec. 31, 2019	$ (16,935,000)	105,000	$ 170,000	$ 531,000	$ 0	$ 0	$ 3,394,000	118,552,000	(132,000)	(139,555,000)
Balance, shares at Dec. 31, 2020	13,138,282		1,000	3,000	1,000	2,000	13,138,000
Balance, amount at Dec. 31, 2020	$ (10,855,000)	105,000	$ 170,000	$ 531,000	$ 276,000	$ 1,639,000	$ 3,403,000	123,109,000	(132,000)	(139,956,000)	$ 0	$ 0	$ 0
Balance, shares at Jun. 30, 2020			1,000	3,000	1,000	1,000	12,764,000
Balance, amount at Jun. 30, 2020	(16,423,000)	105,000	$ 170,000	$ 531,000	$ 276,000	$ 798,000	$ 3,403,000	122,030,000	(132,000)	(143,604,000)
Issuance of preferred stock in financing, shares						1,000
Issuance of preferred stock in financing, amount	741,000					$ 741,000				0
Conversion of debt into common stock, shares							175,000
Conversion of debt into common stock, amount	50,000						$ 0	50,000
Issuance of common stock in financing, shares							50,000
Issuance of common stock in financing, amount	6,000						$ 1,000	5,000		0
Issuance of common stock for payment of Series D preferred dividends, shares					107,000		107,000
Issuance of common stock for payment of Series D preferred dividends, amount	26,000				$ 0		$ 0	26,000		0
Stock based compensation	251,000						$ 0	251,000		0
Accrued series D preferred stock dividends	(46,000)									(46,000)
Net Income	1,575,000									1,575,000
Balance, shares at Sep. 30, 2020			1,000	3,000	108,000	2,000	13,096,000
Balance, amount at Sep. 30, 2020	$ (13,820,000)	105,000	$ 170,000	$ 531,000	$ 276,000	$ 1,539,000	$ 3,404,000	122,362,000	(132,000)	(142,075,000)
Balance, shares at Dec. 31, 2020	13,138,282		1,000	3,000	1,000	2,000	13,138,000
Balance, amount at Dec. 31, 2020	$ (10,855,000)	105,000	$ 170,000	$ 531,000	$ 276,000	$ 1,639,000	$ 3,403,000	123,109,000	(132,000)	(139,956,000)	$ 0	$ 0	$ 0
Issuance of common stock for payment of Series D preferred dividends, shares							83,000
Issuance of common stock for payment of Series D preferred dividends, amount	39,000						$ 0	39,000
Stock based compensation	178,000							178,000
Net Income	(1,626,000)									(1,626,000)
Series F preferred offering, shares											1,000
Series F preferred offering, amount	1,195,000										$ 1,195,000
Series F-2 preferred offering, shares												1,000
Series F-2 preferred offering, amount	404,000											$ 404,000
Conversion of debt and expenses for Series F-2 preferred stock, shares												2,000
Conversion of debt and expenses for Series F-2 preferred stock, amount	2,559,000											$ 2,559,000
Issuance of common stock to finders, shares							98,000
Issuance of common stock to finders, amount	54,000						$ 0	54,000
Series G preferred offering, shares													153,000
Series G preferred offering, amount													$ 0
Series G redemption, shares													(153,000)
Series G redemption, amount													$ 0
Issuance of common stock for payment of Series E preferred dividends, shares							288,000
Issuance of common stock for payment of Series E preferred dividends, amount	118,000						$ 0	118,000
Issuance of warrants to consultants	1,093,000							1,093,000
Warrants issued with debt amount	304,000							304,000
Conversion of warrants from liabilities to equity amount	1,755,000							1,755,000
Accrued preferred dividends	$ (296,000)									(296,000)
Balance, shares at Sep. 30, 2021	13,607,609		1,000	3,000	1,000	2,000	13,607,000				1,000	3,000
Balance, amount at Sep. 30, 2021	$ (5,078,000)	105,000	$ 170,000	$ 531,000	$ 276,000	$ 1,639,000	$ 3,403,000	126,650,000	(132,000)	(141,878,000)	$ 1,195,000	$ 2,963,000	$ 0
Balance, shares at Jun. 30, 2021			1,000	3,000	1,000	2,000	13,297,000				1,000	3,000	62,000
Balance, amount at Jun. 30, 2021	(5,324,000)	105,000	$ 170,000	$ 531,000	$ 276,000	$ 1,639,000	$ 3,403,000	126,353,000	(132,000)	(141,827,000)	$ 1,195,000	$ 2,963,000	$ 0
Issuance of common stock for payment of Series D preferred dividends, shares							22,000
Issuance of common stock for payment of Series D preferred dividends, amount	11,000						$ 0	11,000
Stock based compensation	56,000							56,000
Net Income	68,000									68,000
Series G redemption, shares													(62,000)
Series G redemption, amount													$ 0
Issuance of common stock for payment of Series E preferred dividends, shares							288,000
Issuance of common stock for payment of Series E preferred dividends, amount	118,000						$ 0	118,000
Issuance of warrants to consultants	112,000							112,000
Accrued preferred dividends	$ (119,000)									(119,000)
Balance, shares at Sep. 30, 2021	13,607,609		1,000	3,000	1,000	2,000	13,607,000				1,000	3,000
Balance, amount at Sep. 30, 2021	$ (5,078,000)	$ 105,000	$ 170,000	$ 531,000	$ 276,000	$ 1,639,000	$ 3,403,000	$ 126,650,000	$ (132,000)	$ (141,878,000)	$ 1,195,000	$ 2,963,000	$ 0

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (1,626,000)	$ (2,445,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Bad debt expense	0	13,000
Depreciation	1,000	0
Amortization of debt issuance costs and discounts	250,000	297,000
Amortization of beneficial conversion feature	37,000	78,000
Stock based compensation	178,000	251,000
Change in fair value of warrants	(448,000)	490,000
Extinguishment of derivative liability	(84,000)	296,000
Change in fair value of derivatives	89,000	36,000
Amortization of lease right-of-use-asset	66,000	0
Gain from forgiveness of debt	(578,000)	0
Other non-cash expenses (income)	109,000	0
Change in operating assets and liabilities:
Accounts receivable	0	(1,000)
Inventory	14,000	(5,000)
Other current assets	(88,000)	(532,000)
Other non-current assets	(17,000)	18,000
Accounts payable and accrued liabilities	(435,000)	19,000
Lease liabilities	(41,000)	0
Deferred revenue	237,000	(59,000)
NET CASH USED IN OPERATING ACTIVITIES	(1,751,000)	(1,544,000)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(10,000)	(1,000)
NET CASH USED FOR INVESTING ACTIVITIES	(10,000)	(1,000)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from debt financing	1,248,000	519,000
Payments made on notes payable	(1,415,000)	(959,000)
Payments of debt issuance costs	(86,000)	0
Note payable default penalty	398,000	0
Proceeds from issuance of Series E preferred stock	0	1,539,000
Proceeds from issuance of common stock, net of costs	0	128,000
Proceeds from Series F offering, net of costs	1,436,000	0
Proceeds from Series F-2 offering, net of costs	539,000	0
Proceeds from Series G offering, net of costs	125,000	0
Redemption of Series G preferred stock	(125,000)	0
NET CASH PROVIDED BY FINANCING ACTIVITIES	2,120,000	1,227,000
NET CHANGE IN CASH	359,000	(318,000)
Cash at beginning of period	182,000	899,000
CASH AT END OF PERIOD	541,000	581,000
SUPPLEMENTAL DISCLOSURE FOR OPERATING ACTIVITIES:
Cash paid for interest	552,000	229,000
SUPPLEMENTAL DISCLOSURE FOR NON-CASH INVESTING AND FINANCING ACTIVITIES:
Dividends on preferred stock	296,000	75,000
Debt from related parties exchanged for preferred series F-2	323,000
Issuance of series F-2 preferred stock	2,236,000	377,000
Issuance of warrants to finders in connection with Series F and Series F-2 preferred stock		157,000
Settlement of dividends through common stock issuance	26,000	62,000
Settlement of accounts payable through common stock issuance		1,755,000
Warrants exchanged for fixed price warrants	70,000	304,000
Issuance of common stock as debt repayment	2,832,000
Subscription receivable	635,000
Series C Convertible Preferred Shares
SUPPLEMENTAL DISCLOSURE FOR NON-CASH INVESTING AND FINANCING ACTIVITIES:
Expense for warrants issued to consultants	$ 585,000	$ 0

ORGANIZATION, BACKGROUND, AND B

ORGANIZATION, BACKGROUND, AND BASIS OF PRESENTATION	9 Months Ended
	Sep. 30, 2021
ORGANIZATION, BACKGROUND, AND BASIS OF PRESENTATION
1. ORGANIZATION, BACKGROUND, AND BASIS OF PRESENTATION	1. ORGANIZATION, BACKGROUND, AND BASIS OF PRESENTATION Guided Therapeutics, Inc. (formerly SpectRx, Inc.), together with its wholly owned subsidiary, InterScan, Inc. (formerly Guided Therapeutics, Inc.), collectively referred to herein as the “Company”, is a medical technology company focused on developing innovative medical devices that have the potential to improve healthcare. The Company’s primary focus is the continued commercialization of its LuViva non-invasive cervical cancer detection device and extension of its cancer detection technology into other cancers, including esophageal. The Company’s technology, including products in research and development, primarily relates to biophotonics technology for the non-invasive detection of cancers. Basis of Presentation The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. Therefore, these financial statements should be read in conjunction with our Annual Report on Form 10-K for the fiscal year ended December 31, 2020 filed with the Securities and Exchange Commission (“SEC”) pursuant to Section 13 or 15(d) under the Securities Exchange Act of 1934. The December 31, 2020 balances reported herein are derived from the audited consolidated financial statements for the year ended December 31, 2020. The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year. All intercompany transactions and balances have been eliminated in consolidation. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the Company as of September 30, 2021 and December 31, 2020, and the consolidated results of operations and cash flows for the three and nine-month periods ended September 30, 2021 and 2020 have been included. The Company’s prospects must be considered in light of the substantial risks, expenses and difficulties encountered by entrants into the medical device industry. This industry is characterized by an increasing number of participants, intense competition and a high failure rate. The Company has experienced net losses since its inception and, as of September 30, 2021, it had an accumulated deficit of approximately $141.9 million. To date, the Company has engaged primarily in research and development efforts and the early stages of marketing its products. The Company may not be successful in growing sales for its products. Moreover, required regulatory clearances or approvals may not be obtained in a timely manner, or at all. The Company’s products may not ever gain market acceptance and the Company may not ever generate significant revenues or achieve profitability. The development and commercialization of the Company’s products requires substantial development, regulatory, sales and marketing, manufacturing and other expenditures. The Company expects operating losses to continue for the foreseeable future as it continues to expend substantial resources to complete development of its products, obtain regulatory clearances or approvals, build its marketing, sales, manufacturing and finance capabilities, and conduct further research and development. The Company is not organized by multiple operating segments for the purpose of making operating decisions or assessing performance. Accordingly, the Company operates in one reportable operating segment. The Company’s principal decision makers are the Chief Executive Officer and its Chief Financial Officer. Management believes that its business operates as one reportable segment because: a) the Company measures profit and loss as a whole; b) the principal decision makers do not review information based on any operating segment; c) the Company does not maintain discrete financial information on any specific segment; d) the Company has not chosen to organize its business around different products and services, and e) the Company has not chosen to organize its business around geographic areas. Going Concern The Company’s consolidated financial statements have been prepared and presented on a basis assuming it will continue as a going concern. The factors below raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might be necessary from the outcome of this uncertainty. At September 30, 2021, the Company had a negative working capital of approximately $3.7 million, accumulated deficit of $141.9 million, and incurred a net loss including preferred dividends of $1.9 million for the nine months then ended. Stockholders’ deficit totaled approximately $5.1 million at September 30, 2021, primarily due to recurring net losses from operations. During the nine-month period ended September 30, 2021, the Company raised $3.2 million of funds from the sale of preferred stock and 10% convertible debentures. The Company will need to continue to raise capital in order to provide funding for its operations and FDA approval process. If sufficient capital cannot be raised, the Company will continue its plans of curtailing operations by reducing discretionary spending and staffing levels and attempting to operate by only pursuing activities for which it has external financial support. However, there can be no assurance that such external financial support will be sufficient to maintain even limited operations or that the Company will be able to raise additional funds on acceptable terms, or at all. In such a case, the Company might be required to enter into unfavorable agreements or, if that is not possible, be unable to continue operations, and to the extent practicable, liquidate and/or file for bankruptcy protection. The Company had warrants exercisable for approximately 30.1 million shares of its common stock outstanding at September 30, 2021, with exercise prices ranging between $0.15 and $0.80 per share. Exercises of in-the-money warrants would generate a total of approximately $5.7 million in cash, assuming full exercise, although the Company cannot be assured that holders will exercise any warrants. Management may obtain additional funds through the public or private sale of debt or equity, and grants, if available.

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Sep. 30, 2021
SIGNIFICANT ACCOUNTING POLICIES
2. SIGNIFICANT ACCOUNTING POLICIES	2. SIGNIFICANT ACCOUNTING POLICIES Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant areas where estimates are used include the allowance for doubtful accounts, inventory valuation and input variables for Black-Scholes, Monte Carlo simulations and binomial calculations. The Company uses the Monte Carlo simulations and binomial calculations in the calculation of the fair value of the warrant liabilities and the valuation of embedded conversion options and freestanding warrants. Accounting Standard Updates FASB ASU 2021-04, “ Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options” – FASB ASU NO. 2020-06, “Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity” FASB ASU NO. 2019-12, “ Simplifying the Accounting for Income Taxes A variety of proposed or otherwise potential accounting standards are currently under consideration by standard-setting organizations and certain regulatory agencies. Because of the tentative and preliminary nature of such proposed standards, management has not yet determined the effect, if any that the implementation of such proposed standards would have on the Company’s consolidated financial statements. Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be a cash equivalent. Accounts Receivable The Company performs periodic credit evaluations of its distributors’ financial conditions and generally does not require collateral. The Company reviews all outstanding accounts receivable for collectability on a quarterly basis. An allowance for doubtful accounts is recorded for any amounts deemed uncollectable. Uncollectibility is determined based on the determination that a distributor will not be able to make payment and the time frame has exceeded one year. The Company does not accrue interest receivables on past due accounts receivable. Concentrations of Credit Risk The Company, from time to time during the years covered by these consolidated financial statements, may have bank balances in excess of its insured limits. Management has deemed this a normal business risk. Inventory Valuation All inventories are stated at lower of cost or net realizable value, with cost determined substantially on a “first-in, first-out” basis. Selling, general, and administrative expenses are not inventoried, but are charged to expense when incurred. As of September 30, 2021 and December 31, 2020, our inventories were as follows: (in thousands) September 30, December 31, 2021 2020 Raw materials $ 1,256 $ 1,276 Work-in-progress 86 80 Finished goods 33 7 Inventory reserve (785 ) (758 ) Total inventory $ 590 $ 605 The company periodically reviews the value of items in inventory and provides write-downs or write-offs of inventory based on its assessment of market conditions. Write-downs and write-offs are charged to cost of goods sold. Property and Equipment Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over estimated useful lives of three to seven years. Leasehold improvements are amortized at the shorter of the useful life of the asset or the remaining lease term. Depreciation and amortization expense are included in general and administrative expense on the statement of operations. Expenditures for repairs and maintenance are expensed as incurred. Property and equipment are summarized as follows at September 30, 2021 and December 31, 2020: (in thousands) September 30, December 31, 2021 2020 Equipment $ 1,052 $ 1,042 Software 652 652 Furniture and fixtures 41 41 Leasehold improvements 12 12 Subtotal 1,757 1,747 Less accumulated depreciation (1,746 ) (1,746 ) Property, equipment and leasehold improvements, net $ 11 $ 1 During the nine months ended September 30, 2021 and year ended December 31, 2020, the Company disposed of approximately nil and $647,000 of property and equipment that was fully depreciated, respectively. Depreciation expense related to property and equipment for the nine months ended September 30, 2021 and 2020 was not material. Debt Issuance Costs Debt issuance costs are capitalized and amortized over the term of the associated debt. Debt issuance costs are presented in the balance sheet as a direct deduction from the carrying amount of the debt liability consistent with the debt discount. Patent Costs (Principally Legal Fees) Costs incurred in filing, prosecuting, and maintaining patents are recurring, and expensed as incurred. Maintaining patents are expensed as incurred as the Company has not yet received U.S. FDA approval and recovery of these costs is uncertain. Such costs aggregated to approximately $14,800 and $17,000 for the nine months ended September 30, 2021 and 2020, respectively. Leases A lease provides the lessee the right to control the use of an identified asset for a period of time in exchange for consideration. Right-of-use assets represent the Company’s right to use an underlying asset for the lease term and operating lease liabilities represent the Company’s obligation to make lease payments arising from the lease. The Company determines if an arrangement is a lease at inception. Right-of-use assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. Where an operating lease contains extension options that the Company is reasonably certain to exercise, the extension period is included in the calculation of the right-of-use assets and lease liabilities. The discount rate used to determine the commencement date present value of lease payments is the interest rate implicit in the lease, or when that is not readily determinable, the Company utilizes its secured borrowing rate. Right-of-use assets include any lease payments required to be made prior to commencement and exclude lease incentives. Both right-of-use assets and lease liabilities exclude variable payments not based on an index or rate, which are treated as period costs. The Company’s lease agreements do not contain significant residual value guarantees, restrictions or covenants. See Note 7 – Commitments and Contingencies. Accrued Liabilities Accrued liabilities as of September 30, 2021 and December 31, 2020 are summarized as follows: (in thousands) September 30, December 31, Compensation $ 745 $ 1,094 Professional fees 36 83 Interest 211 1,517 Vacation 44 34 Preferred dividends 298 202 Other accrued expenses 46 65 Total $ 1,380 $ 2,995 Subscription receivables Cash received from investors for common stock shares that has not completed processing is recorded as a liability to subscription receivables. Revenue Recognition ASC 606, Revenue from Contracts with Customers, establishes a single and comprehensive framework which sets out how much revenue is to be recognized, and when. The core principle is that a vendor should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the vendor expects to be entitled in exchange for those goods or services. Revenue will now be recognized by a vendor when control over the goods or services is transferred to the customer. In contrast, revenue-based revenue recognition around an analysis of the transfer of risks and rewards; this now forms one of a number of criteria that are assessed in determining whether control has been transferred. The application of the core principle in ASC 606 is carried out in five steps: · Step 1 – Identify the contract with a customer: a contract is defined as an agreement (including oral and implied), between two or more parties, that creates enforceable rights and obligations and sets out the criteria for each of those rights and obligations. The contract needs to have commercial substance and it is probable that the entity will collect the consideration to which it will be entitled. · Step 2 – Identify the performance obligations in the contract: a performance obligation in a contract is a promise (including implicit) to transfer a good or service to the customer. Each performance obligation should be capable of being distinct and is separately identifiable in the contract. · Step 3 – Determine the transaction price: transaction price is the amount of consideration that the entity can be entitled to, in exchange for transferring the promised goods and services to a customer, excluding amounts collected on behalf of third parties. · Step 4 – Allocate the transaction price to the performance obligations in the contract: for a contract that has more than one performance obligation, the entity will allocate the transaction price to each performance obligation separately, in exchange for satisfying each performance obligation. The acceptable methods of allocating the transaction price include adjusted market assessment approach, expected cost plus a margin approach, and the residual approach in limited circumstances. Discounts given should be allocated proportionately to all performance obligations unless certain criteria are met and reallocation of changes in standalone selling prices after inception is not permitted. · Step 5 – Recognize revenue as and when the entity satisfies a performance obligation: the entity should recognize revenue at a point in time, except if it meets any of the three criteria, which will require recognition of revenue over time: the entity’s performance creates or enhances an asset controlled by the customer, the customer simultaneously receives and consumes the benefit of the entity’s performance as the entity performs, and the entity does not create an asset that has an alternative use to the entity and the entity has the right to be paid for performance to date. The Company did not recognize material revenues during the nine-month periods ended September 30, 2021 or 2020. The Company’s revenues do not require significant estimates or judgments. The Company is not party to contracts that include multiple performance obligations or material variable consideration. Contract Balances The Company defers payments received as revenue until earned based on the related contracts and applying ASC 606 as required. As of September 30, 2021, and December 31, 2020, the Company had $278,000 and $42,000 in deferred revenue, respectively. Significant Distributors As of September 30, 2021, accounts receivable outstanding was $149,000, the outstanding amount was netted against a $126,000 allowance, leaving a balance of $24,000 which was from one distributor. As of December 31, 2020, accounts receivable outstanding was $150,000, the outstanding amount was netted against a $126,000 allowance, leaving a balance of $24,000 which was from one distributor. Research and Development Research and development expenses consist of expenditures for research conducted by the Company and payments made under contracts with consultants or other outside parties and costs associated with internal and contracted clinical trials. All research and development costs are expensed as incurred. Income Taxes The provision for income taxes is determined in accordance with ASC 740, “ Income Taxes The Company has filed its 2020 federal and state corporate tax returns. The Company has entered into an agreed upon payment plan with the IRS for delinquent payroll taxes. The Company has an established payment arrangement for its delinquent state income taxes with the State of Georgia. Although the Company has been experiencing recurring losses, it is obligated to file tax returns for compliance with IRS regulations and that of applicable state jurisdictions. At December 31, 2020, the Company has approximately $61.6 million of net operating losses carryforward available. This net operating loss will be eligible to be carried forward for tax purposes at federal and applicable states level. A full valuation allowance has been recorded related the deferred tax assets generated from the net operating losses. The Company recognizes uncertain tax positions based on a benefit recognition model. Provided that the tax position is deemed more likely than not of being sustained, the Company recognizes the largest amount of tax benefit that is greater than 50.0% likely of being ultimately realized upon settlement. The tax position is derecognized when it is no longer more likely than not of being sustained. The Company classifies income tax related interest and penalties as interest expense and selling, general and administrative expense, respectively, on the consolidated statements of operations. Warrants The Company has issued warrants, which allow the warrant holder to purchase one share of stock at a specified price for a specified period of time. The Company records equity instruments including warrants based on the fair value at the date of issue. The fair value of warrants classified as equity instruments at the date of issuance is estimated using the Black-Scholes Model. The fair value of warrants classified as liabilities at the date of issuance is estimated using the Monte Carlo Simulation or Binomial model. Stock Based Compensation The Company accounts for its stock-based awards in accordance with ASC Subtopic 718, “ Compensation – Stock Compensation The Black-Scholes option pricing model requires the input of certain assumptions that require the Company’s judgment, including the expected term and the expected stock price volatility of the underlying stock. The assumptions used in calculating the fair value of stock-based compensation represent management’s best estimates, but these estimates involve inherent uncertainties and the application of judgment. As a result, if factors change resulting in the use of different assumptions, stock-based compensation expense could be materially different in the future. Beneficial Conversion Features of Convertible Securities The Company has adopted the provisions of ASU 2017-11 to account for the down round features of warrants issued with private placements effective as of January 1, 2020. In doing so, warrants with a down round feature previously treated as derivative liabilities in the consolidated balance sheet and measured at fair value are henceforth treated as equity, with no adjustment for changes in fair value at each reporting period. Previously, the Company accounted for conversion options embedded in convertible notes in accordance with ASC 815. ASC 815 generally requires companies to bifurcate conversion options embedded in convertible notes from their host instruments and to account for them as free-standing derivative financial instruments. ASC 815 provides for an exception to this rule when convertible notes, as host instruments, are deemed to be conventional, as defined by ASC 815-40. The Company accounts for convertible notes deemed conventional and conversion options embedded in non-conventional convertible notes which qualify as equity under ASC 815, in accordance with the provisions of ASC 470-20, which provides guidance on accounting for convertible securities with beneficial conversion features. Accordingly, the Company records, as a discount to convertible notes, the intrinsic value of such conversion options based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt. Conversion options that are not bifurcated as a derivative pursuant to ASC 815 and not accounted for as a separate equity component under the cash conversion guidance are evaluated to determine whether they are beneficial to the investor at inception (a beneficial conversion feature) or may become beneficial in the future due to potential adjustments. The beneficial conversion feature guidance in ASC 470-20 applies to convertible stock as well as convertible debt which are outside the scope of ASC 815. A beneficial conversion feature is defined as a nondetachable conversion feature that is in the money at the commitment date. The beneficial conversion feature guidance requires recognition of the conversion option’s in-the-money portion, the intrinsic value of the option, in equity, with an offsetting reduction to the carrying amount of the instrument. The resulting discount is amortized as a dividend over either the life of the instrument, if a stated maturity date exists, or to the earliest conversion date, if there is no stated maturity date. If the earliest conversion date is immediately upon issuance, the dividend must be recognized at inception. When there is a subsequent change to the conversion ratio based on a future occurrence, the new conversion price may trigger the recognition of an additional beneficial conversion feature on occurrence. The Company also adopted ASU No. 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (ASU 2020-06), which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity’s own equity. Among other changes, ASU 2020-06 removes from U.S. GAAP the liability and equity separation model for convertible instruments with a cash conversion feature, and as a result, after adoption, entities will no longer separately present in equity an embedded conversion feature for such debt. Derivatives The Company reviews the terms of convertible debt issued to determine whether there are embedded derivative instruments, including embedded conversion options, which are required to be bifurcated and accounted for separately as derivative financial instruments. In circumstances where the host instrument contains more than one embedded derivative instrument, including the conversion option, that is required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument. Bifurcated embedded derivatives are initially recorded at fair value and are then revalued at each reporting date with changes in the fair value reported as non-operating income or expense. When the equity or convertible debt instruments contain embedded derivative instruments that are to be bifurcated and accounted for as liabilities, the total proceeds received are first allocated to the fair value of all the bifurcated derivative instruments. The remaining proceeds, if any, are then allocated to the host instruments themselves, usually resulting in those instruments being recorded at a discount from their face value. The discount from the face value of the convertible debt, together with the stated interest on the instrument, is amortized over the life of the instrument through periodic charges to interest expense.

FAIR VALUE OF FINANCIAL INSTRUM

FAIR VALUE OF FINANCIAL INSTRUMENTS	9 Months Ended
	Sep. 30, 2021
FAIR VALUE OF FINANCIAL INSTRUMENTS
3. FAIR VALUE OF FINANCIAL INSTRUMENTS	3. FAIR VALUE OF FINANCIAL INSTRUMENTS The guidance for fair value measurements, ASC820, Fair Value Measurements and Disclosures, establishes the authoritative definition of fair value, sets out a framework for measuring fair value, and outlines the required disclosures regarding fair value measurements. Fair value is the price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. The Company uses a three-tier fair value hierarchy based upon observable and non-observable inputs as follow: · Level 1–Quoted market prices in active markets for identical assets and liabilities; · Level 2–Inputs, other than level 1 inputs, either directly or indirectly observable; and · Level 3–Unobservable inputs developed using internal estimates and assumptions (there is little or no market date) which reflect those that market participants would use. The Company records its derivative activities at fair value. As of September 30, 2021 we had one instrument that we valued for the derivative liability associated with the bifurcated conversion option of the Auctus loan for $400,000 ($700,000 of the $1,100,000 was paid in during the nine months ended September 30, 2021). There was no movement of instruments between fair value hierarchy tiers during the nine months ended September 30, 2021. The following tables present the fair value of those liabilities measured on a recurring basis as of September 30, 2021 and December 31, 2020: Fair Value at September 30, 2021 Level 1 Level 2 Level 3 Total Derivative liability/bifurcated conversion option in connection with Auctus $400,000 loan on December 17, 2019 $ - $ - $ (30 ) $ (30 ) Total long-term liabilities at fair value $ - $ - $ (30 ) $ (30 ) Fair Value at December 31, 2020 Level 1 Level 2 Level 3 Total Warrants issued in connection with Senior Secured Debt $ $ (2,203 ) $ (2,203 ) Derivative liability/bifurcated conversion option in connection with Auctus $400,000 loan on December 17, 2019 - - (25 ) (25 ) Total long-term liabilities at fair value $ - $ - $ (2,228 ) $ (2,228 ) The following is a summary of changes to Level 3 instruments during the nine months ended September 30, 2021: (in thousands) Senior Secured Debt Derivative Total Balance, December 31, 2020 $ (2,203 ) $ (25 ) $ (2,228 ) Change in the terms of warrants previously recorded as a liability and now reclassified to equity 1,755 - 1,755 Change in value due to warrants expiring during the year 448 - 448 Extinguishment of derivative liability due to payoff of $700,000 loan to Auctus - 84 - Change in fair value during the year - (89 ) (89 ) Balance, September 30, 2021 $ - $ (30 ) $ (114 )

STOCKHOLDERS' DEFICIT

STOCKHOLDERS' DEFICIT	9 Months Ended
	Sep. 30, 2021
STOCKHOLDERS' DEFICIT:
4. STOCKHOLDERS' DEFICIT	4. STOCKHOLDERS’ DEFICIT Common Stock The Company has authorized 3,000,000,000 shares of common stock with $0.001 par value. As of September 30, 2021 and December 31,2020 13,607,609 and 13,138,282 shares were issued and outstanding, respectively. During the nine months ended September 30, 2021, the Company issued 469,327 shares of common stock as listed below: Number of Shares Shares issued for payment of Series D dividends 83,065 Shares issued for payment of Series E dividends 288,262 Shares issued for payment of finder fee 98,000 Issued during the nine months ended September 30, 2021 469,327 Summary table of common stock share transactions: Balance at December 31, 2020 13,138,282 Issued in 2021 469,327 Balance at September 30, 2021 13,607,609 Investments During 2021, the Company received 10% debenture unit investments in the amount of $1,130,000 and incurred fees due on these debentures of $86,400. The Company also issued the finders 413,600 warrants for the Company’s common stock shares. The investors received a total of 1,130,000 warrants for common stock shares. The debentures are convertible into 2,260,000 of the Company’s common stock shares. During 2021, the Company received equity investments in the amount of $2,114,000 and incurred fees due on these investments of $139,000. The Company also issued the finders 98,000 of the Company’s common stock shares and 643,700 warrants for the Company’s common stock shares. These investors received a total of 2,114 Series F and Series F-2 preferred stock (if the Investor elects to convert their Series F or Series F-2 preferred stock, each Series F or Series F-2 preferred stock shares converts into 4,000 shares of the Company’s common stock shares). During 2021, the Company finalized an investment by Power Up Lending Group Ltd. Power Up invested $132,000, net to the Company is $125,000, for 153,000 shares of Series G preferred stock. As of September 30, 2021, all Series G preferred shares were redeemed. Debt Exchanges - 2021 On January 8, 2021, the Company made the final payment of $750,000 out of the total $1,500,000 as required by this exchange agreement with GPB. On June 30, 2021, the Company issued 2,236 series F-2 preferred stock shares in accordance with the terms of the agreement (see ) On February 19, 2021, the Company exchanged $100,000 and $85,000 of long-term debt for Dr. Cartwright and Dr. Faupel in exchange for 100 and 85 shares of Series F-2 Preferred Stock, respectively. On March 10, 2021, the Company exchanged $88,000 in accrued consulting fees for Mr. Blumberg for 88 Series F-2 preferred stock shares. On March 22, 2021, the Company entered into an exchange agreement with Richard Fowler. As of December 31, 2020, the Company owed Mr. Fowler $546,214 ($412,624 in deferred salary and $133,590 in accrued interest). The Company exchanged $50,000 of the amount owed of $546,214 for 50 Series F-2 Preferred Shares (convertible into 200,000 common stock shares), and a $150,000 unsecured note. The note accrues interest at the rate of 6% (18% in the event of default) beginning on March 22, 2022 and will be payable in monthly installments of $3,600 for four years, with the first payment being due on March 15, 2022. The effective interest rate of the note is 6.18%. Mr. Fowler also has a short-term note for $26,400 and $18,718 in accrued interest. Mr. Fowler forgave $86,554 and will forgive up to $259,661 if the Company complies with the repayment plan described above. Preferred Stock The Company has authorized 5,000,000 shares of preferred stock with a $.001 par value. The board of directors has the authority to issue these shares and to set dividends, voting and conversion rights, redemption provisions, liquidation preferences, and other rights and restrictions. Series C Convertible Preferred Stock The board designated 9,000 shares of preferred stock as Series C Convertible Preferred Stock, (the “Series C Preferred Stock”). Pursuant to the Series C certificate of designations, shares of Series C preferred stock are convertible into common stock by their holder at any time and may be mandatorily convertible upon the achievement of specified average trading prices for the Company’s common stock. At September 30, 2021 and December 31, 2020, there were 286 shares outstanding with a conversion price of $0.50 per share, such that each share of Series C preferred stock would convert into approximately 2,000 shares of the Company’s common stock; for a total convertible of 572,000 common stock shares, subject to customary adjustments, including for any accrued but unpaid dividends and pursuant to certain anti-dilution provisions, as set forth in the Series C certificate of designations. The conversion price will automatically adjust downward to 80% of the then-current market price of the Company’s common stock 15 trading days after any reverse stock split of the Company’s common stock, and 5 trading days after any conversions of the Company’s outstanding convertible debt. Holders of the Series C preferred stock are entitled to quarterly cumulative dividends at an annual rate of 12.0% until 42 months after the original issuance date (the “Dividend End Date”), payable in cash or, subject to certain conditions, the Company’s common stock. Unpaid accrued dividends were $120,120 as of September 30, 2021. Upon conversion of the Series C preferred stock prior to the Dividend End Date, the Company will also pay to the converting holder a “make-whole payment” equal to the number of unpaid dividends through the Dividend End Date on the converted shares. At September 30, 2021 and December 31, 2020, the “make-whole payment” for a converted share of Series C preferred stock would convert to 200 shares of the Company’s common stock. The Series C preferred stock generally has no voting rights except as required by Delaware law. Upon the Company’s liquidation or sale to or merger with another corporation, each share will be entitled to a liquidation preference of $1,000, plus any accrued but unpaid dividends. In addition, the purchasers of the Series C preferred stock received, on a pro rata basis, warrants exercisable to purchase an aggregate of approximately 1 share of Company’s common stock. The warrants contain anti-dilution adjustments in the event that the Company issues shares of common stock, or securities exercisable or convertible into shares of common stock, at prices below the exercise price of such warrants. As a result of the anti-dilution protection, the Company is required to account for the warrants as a liability recorded at fair value each reporting period. As of September 30, 2021, these warrants had expired. Series C1 Convertible Preferred Stock The board designated 20,250 shares of preferred stock as Series C1 Preferred Stock, of which 1,049 shares were issued and outstanding at September 30, 2021 and December 31, 2020. In addition, some holders separately agreed to exchange each share of the Series C1 Preferred Stock held for one (1) share of the Company’s newly created Series C2 Preferred Stock. In total, for 3,262.25 shares of Series C1 Preferred Stock to be surrendered, the Company issued 3,262.25 shares of Series C2 Preferred Stock. At September 30, 2021 and December 31, 2020, shares of Series C2 had a conversion price of $0.50 per share, such that each share of Series C preferred stock would convert into approximately 2,000 shares of the Company’s common stock. At September 30, 2021 and December 31, 2020, there were 1,049.25 shares outstanding with a conversion price of $0.50 per share, such that each share of Series C1 preferred stock would convert into approximately 2,000 shares of the Company’s common stock; for a total convertible of 2,098,500 common stock shares. The Series C1 preferred stock has terms that are substantially the same as the Series C preferred stock, except that the Series C1 preferred stock does not pay dividends (unless and to the extent declared on the common stock) or at-the-market “make-whole payments” and, while it has the same anti-dilution protections afforded the Series C preferred stock, it does not automatically reset in connection with a reverse stock split or conversion of our outstanding convertible debt. Series C2 Convertible Preferred Stock On August 31, 2018, the Company entered into agreements with certain holders of the Company’s Series C1 Preferred Stock, including the chairman of the Company’s board of directors, and the Chief Operating Officer and a director of the Company pursuant to which those holders separately agreed to exchange each share of the Series C1 Preferred Stock held for one (1) share of the Company’s newly created Series C2 Preferred Stock. In total, for 3,262.25 shares of Series C1 Preferred Stock to be surrendered, the Company issued 3,262.25 shares of Series C2 Preferred Stock. At September 30, 2021 and December 31, 2020, shares of Series C2 had a conversion price of $0.50 per share, such that each share of Series C preferred stock would convert into approximately 2,000 shares of the Company’s common stock; for a total convertible of 6,524,500 common stock shares. The terms of the Series C2 Preferred Stock are substantially the same as the Series C1 Preferred Stock, except that (i) shares of Series C1 Preferred Stock may not be convertible into the Company’s common stock by their holder for a period of 180 days following the date of the filing of the Certificate of Designation (the “Lock-Up Period”); (ii) the Series C2 Preferred Stock has the right to vote as a single class with the Company’s common stock on an as-converted basis, notwithstanding the Lock-Up Period; and (iii) the Series C2 Preferred Stock will automatically convert into that number of securities sold in the next Qualified Financing (as defined in the Exchange Agreement) determined by dividing the stated value ($1,000 per share) of such share of Series C2 Preferred Stock by the purchase price of the securities sold in the Qualified Financing. Series D Convertible Preferred Stock The Board designated 6,000 shares of preferred stock as Series D Preferred Stock, 763 of which remain outstanding as of September 30, 2021. On January 8, 2020, the Company entered into a Stock Purchase Agreement with certain accredited investors (“the Series D Investors”) pursuant to all obligations under the Series D Certificate of Designation. The Series D Investors included the Chief Executive Officer, Chief Operating Officer and a director of the Company. In total, for $763,000 the Company issued 763 shares of Series D Preferred Stock, 1,526,000 common stock shares, 1,526,000 common stock warrants, exercisable at $0.25, and 1,526,000 common stock warrants, exercisable at $0.75. Each Series D Preferred Stock is convertible into 3,000 common stock shares. The Series D Preferred Stock will have cumulative dividends at the rate per share of 10% per annum. The stated value and liquidation preference on the Series D Preferred Stock is $763. The 763 Series D Preferred Shares are convertible into debt at the option of the holder during a prescribed time period. If the Series D Preferred Shares are converted, the Series D preferences are surrendered and the debt is then secured by the Company’s assets. As of September 30, 2021, none of the 763 Series D Preferred Shares have been converted to secured debt. Each share of Series D Preferred is convertible, at any time for a period of 5 years after issuance, into that number of shares of Common Stock, determined by dividing the Stated Value by $0.25, subject to certain adjustments set forth in the Series D Certificate of Designation (the “Series D Conversion Price”). The conversion of Series D Preferred is subject to a 4.99% beneficial ownership limitation, which may be increased to 9.99% at the election of the holder of the Series D Preferred. If the average of the VWAPs (as defined in the Series D Certificate of Designation) for any consecutive 5 trading day period (“Measurement Period”) exceeds 200% of the then Series D Conversion Price and the average daily trading volume of the Common Stock on the primary trading market exceeds 1,000 shares per trading day during the Measurement Period (subject to adjustments), the Company may redeem the then outstanding Series D Preferred, for cash in an amount equal to aggregate Stated Value then outstanding plus accrued but unpaid dividends. During the nine months ended September 30, 2021, the Company issued 83,065 common stock shares for the payment of accrued Series D Preferred Stock dividends. As of September 30, 2021, the Company had accrued dividends of $14,306. Series E Convertible Preferred Stock The Board designated 5,000 shares of preferred stock as Series E Preferred Stock, 1,736 of which remain outstanding. Each share of Series E Preferred is convertible, at any time for a period of 5 years after issuance, into that number of shares of Common Stock, determined by dividing the Stated Value by $0.25, subject to certain adjustments set forth in the Series E Certificate of Designation (the “Series E Conversion Price”). The conversion of Series E Preferred is subject to a 4.99% beneficial ownership limitation, which may be increased to 9.99% at the election of the holder of the Series E Preferred. If the average of the VWAPs (as defined in the Series E Certificate of Designation) for any consecutive 5 trading day period (“Measurement Period”) exceeds 200% of the then Series E Conversion Price and the average daily trading volume of the Common Stock on the primary trading market exceeds 1,000 shares per trading day during the Measurement Period (subject to adjustments), the Company may redeem the then outstanding Series E Preferred, for cash in an amount equal to aggregate Stated Value then outstanding plus accrued but unpaid dividends. Each share of Series E Preferred Stock has a par value of $0.001 per share and a Stated Value equal to $1,000, subject to increase set forth in its Certificate of Designation. Each holder of Series E Preferred Stock is entitled to receive cumulative dividends of 8% per annum, payable annually in cash or, following the listing of the Company’s common stock on certain Canadian trading markets and at the option of the Company, shares of common stock. During the nine months ended September 30, 2021, the Company issued 288,262 common stock shares for the payment of Series E Preferred Stock dividends accrued. As of September 30, 2021, the Company had accrued dividends of $19,811. Series F Convertible Preferred Stock The Company was oversubscribed for its Series F Convertible Preferred Stock, resulting in the requirement to file an additional Certificate of Designation for Series F-2 Convertible Preferred Stock with substantially the same terms as the Series F Convertible Preferred Stock. The Board designated 1,500 shares of preferred stock as Series F Preferred Stock, 1,436 of which are issued and outstanding. During 2021, the Company entered into a Stock Purchase Agreement with certain accredited investors (“the Series F Investors”). In total, for $1,436,000 the Company issued 1,436 shares of Series F Preferred Stock. Each Series F Preferred Stock is convertible into 4,000 common stock shares. The Series F Preferred Stock will have cumulative dividends at the rate per share of 6% per annum. The stated value and liquidation preference on the Series F Preferred Stock is $1,436. Each share of Series F Preferred is convertible, at any time for a period of 5 years after issuance, into that number of shares of Common Stock, determined by dividing the Stated Value by $0.25, subject to certain adjustments set forth in the Series F Certificate of Designation (the “Series F Conversion Price”). The conversion of Series F Preferred is subject to a 4.99% beneficial ownership limitation, which may be increased to 9.99% at the election of the holder of the Series F Preferred. If the average of the VWAPs (as defined in the Series F Certificate of Designation) for any consecutive 5 trading day period (“Measurement Period”) exceeds 200% of the then Series F Conversion Price and the average daily trading volume of the Common Stock on the primary trading market exceeds 1,000 shares per trading day during the Measurement Period (subject to adjustments), the Company may redeem the then outstanding Series F Preferred, for cash in an amount equal to aggregate Stated Value then outstanding plus accrued but unpaid dividends. As of September 30, 2021, the Company had not issued shares as payment of Series F Preferred Stock dividends. As of September 30, 2021, the Company had accrued dividends of $44,199. Series F-2 Convertible Preferred Stock The Board designated 3,500 shares of preferred stock as Series F-2 Preferred Stock, 3,237 of which are issued and outstanding. During 2021, the Company entered into a Stock Purchase Agreement with certain accredited investors (“the Series F-2 Investors”). In total, for $678,000 the Company issued 678 shares of Series F-2 Preferred Stock. In addition, the Company exchanged outstanding debt of $2,559,000 for 2,559 shares of Series F-2 Preferred Stock. Each Series F-2 Preferred Stock is convertible into 4,000 common stock shares. The Series F-2 Preferred Stock will have cumulative dividends at the rate per share of 6% per annum. The stated value and liquidation preference on the Series F-2 Preferred Stock is $3,339. Below is a summary of the debt exchanges. On January 8, 2021, the Company made the final payment of $750,000 out of the total $1,500,000 as required by this exchange agreement with GPB. On February 24, 2021, the Company agree to issue 2,236 Series F-2 preferred stock shares in accordance with the terms of the agreement (see Note 10 – Convertible Debt). On February 19, 2021, the Company exchanged $100,000 and $85,000 of long-term debt for Dr. Cartwright and Dr. Faupel in exchange for 100 and 85 shares of Series F-2 Preferred Stock, respectively. On March 10, 2021, the Company exchanged $88,000 in accrued consulting fees for Mr. Blumberg for 88 shares of Series F-2 preferred stock shares. On March 22, 2021, the Company exchanged $50,000 of the amount owed of $546,214 for 50 shares of Series F-2 Preferred Shares (convertible into 200,000 common stock shares), a $150,000 unsecured note. Mr. Fowler forgave $86,554 and will forgive up to $259,661 if the Company complies in full with the repayment plan. Each share of Series F-2 Preferred is convertible, at any time for a period of 5 years after issuance, into that number of shares of Common Stock, determined by dividing the Stated Value by $0.25, subject to certain adjustments set forth in the Series F-2 Certificate of Designation (the “Series F-2 Conversion Price”). The conversion of Series F-2 Preferred is subject to a 4.99% beneficial ownership limitation, which may be increased to 9.99% at the election of the holders of the Series F-2 Preferred. If the average of the VWAPs (as defined in the Series F-2 Certificate of Designation) for any consecutive 5 trading day period (“Measurement Period”) exceeds 200% of the then Series F-2 Conversion Price and the average daily trading volume of the Common Stock on the primary trading market exceeds 1,000 shares per trading day during the Measurement Period (subject to adjustments), the Company may redeem the then outstanding Series F-2 Preferred, for cash in an amount equal to aggregate Stated Value then outstanding plus accrued but unpaid dividends. As of September 30, 2021, the Company had not issued shares as payment of Series F-2 Preferred Stock dividends. As of September 30, 2021, the Company had accrued dividends of $99,593. Powerup (Series G Convertible Preferred Stock) During January 2021, the Company finalized an investment by Power Up Lending Group Ltd. Power Up invested $78,500, net to the Company is $75,000, for 91,000 shares of Series G preferred stock with additional tranches of financing up to $925,000 in the aggregate over the terms of the Series G preferred stock. Series G will be non-voting on any matters requiring shareholder vote. The Series G Preferred Stock will have cumulative dividends at the rate per share of 8% per annum. At any time during the period indicated below, after the date of the issuance of shares of Series G preferred stock, the Company will have the right, at the Company’s option, to redeem all of the shares of Series G preferred stock by paying an amount equal to: (i) the number of shares of Series G preferred stock multiplied by then stated value (including accrued dividends); (ii) multiplied by the corresponding percentage as follows: Day 1-60, 105%; Day 61-90, 110%; Day 91-120, 115%; and Day 121-180, 122%. After the expiration of the 180 days following the issuance date, except for mandatory redemption, the Company shall have no right to redeem the Series G preferred stock. Mandatory redemption occurs within 24 months. In addition, if the Company does not redeem the Series G preferred stock then Power Up will have the option to convert to common stock shares. The variable conversion price will be the value equal to a discount of 19% off of the trading price; which is calculated as the average of the three lowest closing bid prices over the last fifteen trading days. The conversion of Series G Preferred is subject to a 4.99% beneficial ownership limitation, which may be increased to 9.99% at the election of the holder of the Series G Preferred. The Company has redeemed all of the Series G preferred stock and the balance is paid. During February 2021, the Company finalized an investment by Power Up Lending Group Ltd. Power Up invested $53,500, net to the Company is $50,000, for 62,000 shares of Series G preferred stock with additional tranches of financing up to $925,000 in the aggregate over the terms of the Series G preferred stock. Series G will be non-voting on any matters requiring shareholder vote. The Series G Preferred Stock will have cumulative dividends at the rate per share of 8% per annum. At any time during the period indicated below, after the date of the issuance of shares of Series G preferred stock, the Company will have the right, at the Company’s option, to redeem all of the shares of Series G preferred stock by paying an amount equal to: (i) the number of shares of Series G preferred stock multiplied by then stated value (including accrued dividends); (ii) multiplied by the corresponding percentage as follows: Day 1-60, 105%; Day 61-90, 110%; Day 91-120, 115%; and Day 121-180, 122%. After the expiration of the 180 days following the issuance date, except for mandatory redemption, the Company shall have no right to redeem the Series G preferred stock. Mandatory redemption occurs within 24 months. In addition, if the Company does not redeem the Series G preferred stock then Power Up will have the option to convert to common stock shares. The variable conversion price will be the value equal to a discount of 19% off of the trading price; which is calculated as the average of the three lowest closing bid prices over the last fifteen trading days. The conversion of Series G Preferred is subject to a 4.99% beneficial ownership limitation, which may be increased to 9.99% at the election of the holder of the Series G Preferred. Due to the mandatory redemption feature of the Series G preferred stock, the total amount of proceeds of $125,000 was recorded as a liability. On June 4, 2021, the Company redeemed the January 2021 investment of $75,000 for $114,597, this $39,597 difference was recorded as interest expense. On July 8, 2021, the Company redeemed the February 2021 investment of $50,000 for $78,094. The difference of $28,094 was recorded as interest expense. As of September 30, 2021, the amount outstanding was nil. Warrants The following table summarizes transactions involving the Company’s outstanding warrants to purchase common stock for the nine months ended September 30, 2021: Warrants Weighted-Average Exercise Price Per Share Outstanding, January 1, 2021 28,324,275 $ 0.25 Warrants granted 3,504,300 $ 0.48 Warrants cancelled/expired (1,729,662 ) $ 0.04 Outstanding, September 30, 2021 30,098,913 $ 0.29

STOCK OPTIONS

STOCK OPTIONS	9 Months Ended
	Sep. 30, 2021
STOCK OPTIONS
5. STOCK OPTIONS	5. STOCK OPTIONS The new Stock Plan (the “Plan”) allows for the issuance of incentive stock options, nonqualified stock options, and stock purchase rights. The exercise price of options was determined by the Company’s board of directors, but incentive stock options were granted at an exercise price equal to the fair market value of the Company’s common stock as of the grant date. Options historically granted have generally become exercisable over four years and expire ten years from the date of grant. The plan provides for stock options to be granted up to 10% of the outstanding common stock shares. The following table summarizes the Company’s stock option activity and related information for the nine months ended September 30, 2021: Number of Shares Weighted-Average Exercise Price Per Share Weighted-Average Remaining Contractual Life Aggregate Intrinsic Value of In-the-Money Options Options outstanding as of January 1, 2021 1,800,000 $ 0.49 Options granted 25,000 $ 0.48 Options exercised - $ - Options forfeited (167,614 ) $ 0.48 Options expired - $ - Options outstanding as of September 30, 2021 1,657,386 $ 0.49 8.8 years $ 127 Options exercisable as of September 30, 2021 1,009,705 $ 0.49 8.8 years $ 71 The aggregate intrinsic value is calculated as the difference between the Company’s closing stock price as of September 30, 2021 and the exercise price, multiplied by the number of options. As of September 30, 2021, there was $312,693 total unrecognized stock-based compensation expense. Such costs are expected to be recognized over a weighted average period of approximately 1.75 years. The weighted-average fair value of awards granted was $0.47 and $0.48 during the nine months ended September 30, 2021 and 2020, respectively. The Company recognizes compensation expense for stock option awards on a straight-line basis over the applicable service period of the award. The service period is generally the vesting period. The following weighted-average assumptions were used to calculate stock-based compensation expense: September 30, September 30, 2021 2020 Expected term (years) 10 years 10 years Volatility 153.1 % 153.12 % Risk-free interest rate 0.98 % 0.98 % Dividend yield 0.00 % 0.00 %

LITIGATION AND CLAIMS

LITIGATION AND CLAIMS	9 Months Ended
	Sep. 30, 2021
COMMITMENTS AND CONTINGENCIES (Note 7)
6. LITIGATION AND CLAIMS	6. LITIGATION AND CLAIMS From time to time, the Company may be involved in various legal proceedings and claims arising in the ordinary course of business. Management believes that the dispositions of these matters, individually or in the aggregate, are not expected to have a material adverse effect on the Company’s financial condition. However, depending on the amount and timing of such disposition, an unfavorable resolution of some or all of these matters could materially affect the future results of operations or cash flows in a particular year. As of September 30, 2021, and December 31, 2020, there was no accrual recorded for any potential losses related to pending litigation.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Sep. 30, 2021
COMMITMENTS AND CONTINGENCIES (Note 7)
7. COMMITMENTS AND CONTINGENCIES	7. COMMITMENTS AND CONTINGENCIES Operating Leases The below table presents total operating lease right-of-use assets and lease liabilities as of September 30, 2021: (in thousands) Nine Months Ended September 30, 2021 Operating lease right-of-use assets $ 388 Operating lease liabilities $ 407 The table below presents the maturities of operating lease liabilities as of September 30, 2021: (in thousands) Operating Leases 2021 $ 26 2022 108 2023 112 2024 115 2025 118 Thereafter 50 Total future lease payments 529 Less: discount (122 ) Total lease liabilities $ 407 The table below presents the weighted-average remaining lease term and discount rate used in the calculation of operating lease right-of-use assets and lease liabilities: Nine Months Ended September 30, 2021 Weighted average remaining lease term (years) 4.5 Weighted average discount rate 11.4 % Related Party Contracts On June 5, 2016, the Company entered into a license agreement with Shenghuo Medical, LLC pursuant to which the Company granted Shenghuo an exclusive license to manufacture, sell and distribute LuViva in Taiwan, Brunei Darussalam, Cambodia, Laos, Myanmar, Philippines, Singapore, Thailand, and Vietnam. Shenghuo was already the Company’s exclusive distributor in China, Macau and Hong Kong, and the license extended to manufacturing in those countries as well. Under the terms of the license agreement, once Shenghuo was capable of manufacturing LuViva in accordance with ISO 13485 for medical devices, Shenghuo would pay the Company a royalty equal to $2.00 or 20% of the distributor price (subject to a discount under certain circumstances), whichever is higher, per disposable distributed within Shenghuo’s exclusive territories. In connection with the license grant, Shenghuo was to underwrite the cost of securing approval of LuViva with Chinese Food and Drug Administration. At its option, Shenghuo also would provide up to $1.0 million in furtherance of the Company’s efforts to secure regulatory approval for LuViva from the U.S. Food and Drug Administration, in exchange for the right to receive payments equal to 2% of the Company’s future sales in the United States, up to an aggregate of $4.0 million. Pursuant to the license agreement, Shenghuo had the option to have a designee appointed to the Company’s board of directors (current director Richard Blumberg is the designee). On September 6, 2016, the Company entered into a royalty agreement with one of its directors, John Imhoff, and another stockholder, Dolores Maloof, pursuant to which the Company sold to them a royalty of future sales of single-use cervical guides for LuViva. Under the terms of the royalty agreement, and for consideration of $50,000, the Company will pay them an aggregate perpetual royalty initially equal to $0.10, and from and after October 2, 2016, equal to $0.20, for each disposable that the Company sells (or that is sold by a third party pursuant to a licensing arrangement with the Company). On January 22, 2020, the Company entered into a promotional agreement with a related party, which is partially owned by Mr. Blumberg, to provide investor and public relations services for a period of two years. As compensation for these services, the Company will issue a total of 5,000,000 warrants, broken into four tranches of 1,250,000. The warrants have a strike price of $0.25 and are subject to vesting based upon the close of the Series D offering and a minimum share price based on the 30-day VWAP. If the minimum share price per the terms of the agreement is not achieved, the warrants will expire three years after the issuance date. The warrants were valued using the Black Scholes model on the grant date of January 22, 2020, which resulted in a total fair value of $715,000. The Company did not appropriately expense the services received in connection with this agreement in 2020. During the nine months ended September 30, 2021, the Company recognized $556,111 of consulting expenses as a result of this agreement, which includes twelve months of expense for the year ended December 31, 2020. If the Company had properly accounted for the straight-line expensing of these services in 2020, net loss would have increased by $318,000 for a total net loss of $719,000 for the year ended December 31, 2020 and accumulated deficit would have increased to $140.2 million as of December 31, 2020. Unrecognized consulting expense to be recognized under this agreement is $158,889 as of September 30, 2021. On March 10, 2021, the Company entered into a consulting agreement with Richard Blumberg. As a result of the consulting agreement Mr. Blumberg provided $350,000, which was recorded to subscription receivable, to the Company in exchange for the following: (1) on September 26, 2021, 900,000 3-year warrants with an exercise price of $0.30 and 400,000 common stock shares; (2) on March 26, 2022, 900,000 3-year warrants with an exercise price of $0.40 and 400,000 common stock shares; (3) on September 26, 2022, 900,000 3-year warrants with an exercise price of $0.50 and 400,000 common stock shares; and (4) on March 26, 2023, 900,000 3-year warrants with an exercise price of $0.60 and 400,000 common stock shares. On September 30, 2021, the consulting agreement was amended to clarify that $350,000 is not intended to be debt and will not be required to be repaid in cash. Additionally, issuance of the warrants is now predicated on the Company receiving funding receipts of $1,000,000, whether from a financing, series of financing, or gross sales. The amended agreement clarified that the warrants issued to Mr. Blumberg are compensation for services, which involve obtaining financing. The Company will recognize expense for the services equal to the fair value of the warrants issued to Mr. Blumberg as the services are provided, which will coincide with the successful execution of a financing agreement over $1,000,000. The Company concluded that as of September 30, 2021, there is no longer a liability due to Mr. Blumberg of $350,000. The liability was written off in the third quarter of 2021 and a gain of $350,000 was recognized in non-operating income. Other Commitments On July 24, 2019, Shandong Yaohua Medical Instrument Corporation (“SMI”), agreed to modify its existing agreement. Under the terms of this modification, the Company agreed to grant (1) exclusive manufacturing rights, excepting the disposable cervical guides for the Republic of Turkey, and the final assembly rights for Hungary, and (2) exclusive distribution and sales for LuViva in jurisdictions, subject to the following terms and conditions. First, SMI shall complete the payment for parts, per the purchase order, for five additional LuViva devices. Second, in consideration for the $885,144 that the Company received, SMI will receive 12,147 common stock shares. Third, SMI shall honor all existing purchase orders it has executed to date with the Company, in order to maintain jurisdiction sales and distribution rights. If SMI needs to purchase cervical guides then it will do so at a cost including labor, plus ten percent markup. The Company will provide 200 cervical guides at no cost for the clinical trials. Fourth, the Company and SMI will make best efforts to sell devices after CFDA approval. With an initial estimate of year one sales of 200 LuViva devices; year two sales of 500 LuViva devices; year three sales of 1,000 LuViva devices; and year four sales of 1,250 LuViva devices. Fifth, SMI shall pay for entire costs of securing approval of LuViva with the Chinese FDA. Sixth, SMI shall arrange, at its sole cost, for a manufacturer in China to build tooling to support manufacturing. In addition, SMI retains the right to manufacture for China, Hong Kong, Macau and Taiwan, where SMI has distribution and sales rights. For each single-use cervical guide sold by SMI in the jurisdictions, SMI shall transfer funds to escrow agent at a rate of $1.90 per device chip. If within 18 months of the license’s effective date, SMI fails to achieve commercialization of LuViva in China, SMI shall no longer have any rights to manufacture, distribute or sell LuViva. Commercialization is defined as: filing an application with the Chinese FDA for the approval of LuViva; any assembly or manufacture of the devices or disposables that begins in China; and purchase of at least 10 devices and disposables for clinical evaluations and regulatory use and or sales in the jurisdictions. On August 12, 2021, the Company executed an amendment to its agreement with SMI, which established a payment schedule for the balance owed by SMI to the Company for outstanding purchase orders. The Company received $233,635 from SMI during the three months ended September 30, 2021. The remaining balance owed for outstanding purchase orders was $277,000 as of September 30, 2021. Under the terms of the amended agreement, the parties agreed that if by October 30, 2022, SMI fails to achieve commercialization of LaViva in China, SMI shall no longer have any rights to manufacture, distribute or sell LaViva. Contingencies Based on the current outbreak of the Coronavirus SARS-CoV-2, the pathogen responsible for COVID-19, which has already had an impact on financial markets, there could be additional repercussions to the Company’s operating business, including but not limited to, the sourcing of materials for product candidates, manufacture of supplies for preclinical and/or clinical studies, delays in clinical operations, which may include the availability or the continued availability of patients for trials due to such things as quarantines, conduct of patient monitoring and clinical trial data retrieval at investigational study sites. The future impact of the outbreak is highly uncertain and cannot be predicted, and the Company cannot provide any assurance that the outbreak will not have a material adverse impact on the Company’s operations or future results or filings with regulatory health authorities. The extent of the impact to the Company, if any, will depend on future developments, including actions taken to contain the coronavirus.

NOTES PAYABLE

NOTES PAYABLE	9 Months Ended
	Sep. 30, 2021
NOTES PAYABLE
8. NOTES PAYABLE	8. NOTES PAYABLE Notes Payable in Default At September 30, 2021 and December 31, 2020, the Company maintained notes payable to both related and non-related parties totaling approximately nil and $329,000, respectively. These notes are short term, straight-line amortizing notes. The notes carry annual interest rates between 0% and 10% and have default rates as high as 20%. As described in Note 4: “Stockholders’ Deficit,” During the three months ended September 30, 2021, the Company obtained a legal opinion as to how the applicable statute of limitations effects the status of the note payable due to Mr. Mermelstein and determined that the Company can no longer be required to repay the note as of September 30, 2021. As a result of the opinion, the note payable of $285,244 and accrued interest of $32,945 was written off during the third quarter of 2021. During 2021, notes payable of $1,000 due to Dr. Cartwright were paid off and notes payable of $26,000 due to Mr. Fowler were brought current and not in default. The note payable to GPB was exchanged as part of the exchange as described in Note 10: The following table summarizes notes payable in default, including related parties (in thousands): September 30, 2021 December 31, 2020 Mr. Mermelstein $ - $ 285 Dr. Cartwright - 1 Mr. Fowler - 26 GPB - 17 Notes payable in default $ - $ 329 The notes payable in default to related parties was $27,000 of the $329,000 balance as of December 31, 2020. Short Term Notes Payable At September 30, 2021 and December 31, 2020, the Company maintained short term notes payable to both related and non-related parties totaling $132,812 and $96,000, respectively. These notes are short term, straight-line amortizing notes. The notes carry annual interest rates between 4.3% and 16%, or 18% in the event of default. On July 4, 2021, the Company entered into a premium finance agreement to finance its insurance policies totaling $117,560. The note requires monthly payments of $11,968, including interest at 4.3% and matured in April 2022. As of September 30, 2021, the balance on that note was $82,881. On July 4, 2020, the Company entered into a premium finance agreement to finance its insurance policies totaling $109,000. The note requires monthly payments of $11,299, including interest at 4.968% and matured in April 2021. As of September 30, 2021, the balance was paid. During 2019, the Company issued promissory notes to Mr. Cartwright and Mr. Faupel, in the amounts of approximately $41,000 and $5,000, respectively. The notes were initially issued with 0% interest, however interest increased to 6.0% interest 90 days after the Company received $1,000,000 in financing proceeds. On December 21, 2016 and January 19, 2017, the Company issued promissory notes to Mr. Fowler, in the amounts of approximately $12,500 and $13,900. The notes were initially issued with 0% interest and then went into default with an interest rate of 18%. As part of the March 22, 2021 exchange agreement these notes were combined into one short term note payable of $26,400 and $18,718 in principal and interest of the two previous notes, respectively, for the total balance of $45,118. The aforementioned agreement brought the note current and will accrue interest at a rate of 6.0%. The note carries a monthly payment of $3,850. As of September 30, 2021, the outstanding principal balance on the note was $12,601. At December 31, 2020 this note was recorded in the Notes payable in default section of the consolidated Balance Sheet. The following table summarizes short-term notes payable, including related parties: September 30, 2021 December 31, 2020 Dr. Cartwright $ 37 $ 46 Dr. Faulpel - 5 Mr. Fowler 13 - Premium Finance (insurance) 83 45 Short-term notes payable $ 133 $ 96 The short-term notes payable past due to related parties was $50,000 at September 30, 2021 and $51,000 of the $96,000 balance at December 31, 2020.

SHORT-TERM CONVERTIBLE DEBT

SHORT-TERM CONVERTIBLE DEBT	9 Months Ended
	Sep. 30, 2021
SHORT-TERM CONVERTIBLE DEBT
9. SHORT-TERM CONVERTIBLE DEBT	9. SHORT-TERM CONVERTIBLE DEBT Short-term Convertible Notes Payable Auctus On December 17, 2019, the Company entered into a securities purchase agreement and convertible note with Auctus. The convertible note issued to Auctus will be for a total of $2.4 million. The first tranche of $700,000 was received in December 2019 and matures December 17, 2021 and accrues interest at a rate of ten percent (10%). The note may not be prepaid in whole or in part except as otherwise explicitly allowed. Any amount of principal or interest on the note which is not paid when due shall bear interest at the rate of the lessor of 24% or the maximum permitted by law (the “default interest”). The variable conversion prices shall equal the lesser of: (i) the lowest trading price on the issue date, and (ii) the variable conversion price. The variable conversion price shall mean 95% multiplied by the market price (the market price means the average of the five lowest trading prices during the period beginning on the issue date and ending on the maturity date), minus $0.04 per share, provided however that in no event shall the variable conversion price be less than $0.15. If an event of default under this note occurs and/or the note is not extinguished in its entirety prior to December 17, 2020 the $0.15 price shall no longer apply. In connection with the first tranche of $700,000, the Company issued 7,500,000 warrants to purchase common stock at an exercise price of $0.20. The fair value of the warrants at the date of issuance was $745,972 and was $635,000 allocated to the warrant liability and a loss of $110,972 was recorded at the date of issuance for the amount of the fair value in excess of the net proceeds received of $635,000. The $700,000 proceeds were received net of debt issuance costs of $65,000 (net proceeds of $635,000, after administrative and legal expenses Company received $570,000). The Company used $65,000 of the proceeds to make a partial payment of the $89,250 convertible promissory note issued on July 3, 2018 to Auctus. As a result of the payment of the Company made a $700,000 payment on June 1, 2021, which resulted in a prepayment penalty of $350,000 being assessed to the Company. The Company recorded this prepayment penalty as interest expense. Interest will not be assessed on the prepayment penalty. As of September 30, 2021 and December 31, 2020, $350,000 and $700,000, respectively, remained outstanding. As of September 30, 2021, accrued interest was paid in full and at December 31, 2020 $73,889 remained outstanding. Further, as September 30, 2021 and December 31, 2020, the Company had unamortized debt issuance costs of nil and $31,146, respectively and an unamortized debt discount on warrants of nil and $304,271, respectively and providing a net balance of $350,000 and $364,583, respectively. On May 27, 2020, the Company received the second tranche in the amount of $400,000, from the December 17, 2019 securities purchase agreement and convertible note with Auctus. The net amount paid to the Company was $313,000 This second tranche is part of the convertible note issued to Auctus for a total of $2.4 million of which $700,000 has already been provided by Auctus. The notes maturity date is December 17, 2021 and an interest rate of ten percent (10%). The note may not be prepaid in whole or in part except as otherwise explicitly allowed. Any amount of principal or interest on the note which is not paid when due shall bear interest at the rate of the lessor of 24% or the maximum permitted by law (the “default interest”). The variable conversion prices shall equal the lesser of: (i) the lowest trading price on the issue date, and (ii) the variable conversion price. The variable conversion price shall mean 95% multiplied by the market price (the market price means the average of the five lowest trading prices during the period beginning on the issue date and ending on the maturity date), minus $0.04 per share, provided however that in no event shall the variable conversion price be less than $0.15. If an event of default under this note occurs and/or the note is not extinguished in its entirety prior to December 17, 2020 the $0.15 price shall no longer apply. The last tranche of $1.3 million will be received within 60 days of the S-1 registration statement becoming effective. The conversion price of the notes will be at market value with a minimum conversion amount of $0.15. In addition, as part of this transaction the Company was required to pay a 2.0% fee to a registered broker-dealer. As of September 30, 2021 and December 31, 2020, $400,000 remained outstanding and accrued interest of $54,556 and $24,222, respectively. Further, as of September 30, 2021 and December 31, 2020, the Company had unamortized debt issuance costs of $21,961 and $47,086, providing a net balance of $432,595 and $377,136. As of September 30, 2021 the bifurcated/derivative liability was $30,083. Convertible Notes in Default On March 31, 2020, we entered into a securities purchase agreement with Auctus Fund, LLC for the issuance and sale to Auctus of $112,750 in aggregate principal amount of a 12% convertible promissory note. On June 30, 2020, we issued the note to Auctus and issued 250,000 five-year common stock warrants at an exercise price of $0.16. On April 3, 2020, we received net proceeds of $100,000. The note matured on January 26, 2021 and accrues interest at a rate of 12% per year. We may not prepay the note, in whole or in part. After the 90 th The following table summarizes the Short-term Convertible Notes Payable, including debt in default (in thousands): September 30, 2021 December 31, 2020 Auctus Tranche 1 - 700 Auctus Tranche 2 $ 400 $ 400 Auctus prepayment penalty 350 - Auctus (March 31, 2020 Note) 161 113 Debt discount and issuance costs to be amortizaed (22 ) (262 ) Convertible notes payable - short-term $ 889 $ 951 Troubled Debt Restructuring During 2021, the prepayment penalty to Auctus was recorded as debt extinguished for Short-term Convertible Notes Payable. This prepayment penalty resulted in a loss of $350,000. In addition, the gain recognized for the extinguishment of the derivative liability due to the payoff of the $700,000 loan to Auctus of $84,000 was recorded. This debt extinguished met the criteria for troubled debt. The basic criteria are that the borrower is troubled, i.e., they are having financial difficulties, and a concession is granted by the creditor. Due to the Company being in default on several of its loans the debt is considered troubled debt.

CONVERTIBLE DEBT

CONVERTIBLE DEBT	9 Months Ended
	Sep. 30, 2021
SHORT-TERM CONVERTIBLE DEBT
10. CONVERTIBLE DEBT	10. CONVERTIBLE DEBT Convertible notes payable, past due Senior Secured Promissory Note As of September 30, 2021, all Senior Secured debt due to GPB had been exchanged for 2,236 Series F-2 preferred stock shares in accordance with the terms of the January 15, 2020 exchange agreement. In addition, the common stock purchase warrant exercise price had been adjusted to $0.20 and the number of common stock shares exchangeable for was 7,185,000. The exchange agreement was subject to the Company meeting repayment conditions, which the Company did. Those conditions involved in part the repayment of $450,000, $100,000 and $950,000 for the completion of each Auctus financing tranche. Further on September 2, 2020, the Company made a payment of $50,000, which provided the Company a four-month forbearance as well as paying an additional $150,000 to reduce the balance outstanding at that time. On January 8, 2021, the Company made the final payment of $750,000 as required by this exchange agreement with GPB. On February 12, 2016, the Company entered into a securities purchase agreement with GPB Debt Holdings II LLC (“GPB”) for the issuance of a $1,437,500 senior secured convertible note for an aggregate purchase price of $1,029,000 (representing an original issue discount of $287,500 and debt issuance costs of $121,000). On May 28, 2016, the balance of the note was increased by $87,500 for a total principal balance of $1,525,000. On December 7, 2016, the Company entered into an exchange agreement with GPB and as a result the principal balance increased by a transfer $312,500 for a total principal balance of $1,837,500. In connection with the transaction, on February 12, 2016, the Company and GPB entered into a four-year consulting agreement, pursuant to which the investor will provide management consulting services to the Company in exchange for a royalty payment, payable quarterly, equal to 3.85% of the Company’s revenues from the sale of products. On August 20, 2021, the Company made a royalty payment to GPB. As of September 30, 2021 and December 31, 2020, the balance related to royalties due to GPB was nil and $35,000, respectively. Based on the consulting agreement GPB will no longer earn royalties. As of December 31, 2020, the balance due on the convertible debt was $1,709,414, consisting of principal of $1,362,384 and a prepayment penalty of $347,030. Interest accrued on the note totaled $1,233,637 at December 31, 2020, and is included in accrued expenses on the accompanying consolidated balance sheet. The Company used a placement agent in connection with the transaction.For its services, the placement agent received a cash placement fee equal to 4% of the aggregate gross proceeds from the transaction and a warrant to purchase shares of common stock equal to an aggregate of 6% of the total number of shares underlying the securities sold in the transaction, at an exercise price equal to, and terms otherwise identical to, the warrant issued to the investor. Finally, the Company agreed to reimburse the placement agent for its reasonable out-of-pocket expenses. The warrants issued to the placement agent expired during the nine months ended September 30, 2021. The following table summarizes the convertible notes past due (in thousands): September 30, 2021 December 31, 2020 GBP $ - $ 1,709 GHS - 181 Auctus - 40 Convertible notes payable $ - $ 1,930 Troubled Debt Restructuring During 2021, the Company restructured debt with GPB resulting in the exchange of $1,709,000 of convertible debt. This debt restructure met the criteria for troubled debt. The basic criteria are that the borrower is troubled, i.e., they are having financial difficulties, and a concession is granted by the creditor.

LONG TERM DEBT

LONG TERM DEBT	9 Months Ended
	Sep. 30, 2021
LONG TERM DEBT
11. LONG-TERM DEBT	11. LONG-TERM DEBT Long-term Debt – Related Parties On July 24, 2019, Dr. Faupel and Mr. Cartwright agreed to an addendum to the debt restructuring exchange agreement and to modify the terms of the original exchange agreement. Under this modification Dr. Faupel and Mr. Cartwright agreed to extend the note to be due in full on the third anniversary of that agreement. The modification also included simple interest at a 6% rate, with the principal and accrued interest due in total at the date of maturity or February 18, 2023. During the quarter ended September 30, 2018, the Company entered into an exchange agreement dated July 14, 2018, Dr. Faupel, agreed to exchange outstanding amounts due to him for loans, interest, bonus, salary and vacation pay in the amount of $661,000 for a $207,000 promissory note dated September 4, 2018. As a result of the exchange agreement, the Company recorded a gain for extinguishment of debt of $199,000 and a capital contribution of $235,000 during the year ended December 31, 2018. The resulting difference of $20,000 was recorded to accrued interest. In the July 20, 2018 exchange agreement, Dr, Cartwright, agreed to exchange outstanding amounts due to him for loans, interest, bonus, salary and vacation pay in the amount of $1,621,000 for a $319,000 promissory note dated September 4, 2018. As a result of the exchange agreement, the Company recorded a gain for extinguishment of debt of $840,000 and a capital contribution of $432,000 during the year ended December 31, 2018. The resulting difference of $30,000 was recorded to accrued interest and elimination of debt. On February 19, 2021, the Company entered into new promissory notes replacing the original notes from September 4, 2018, with Mark Faupel and Gene Cartwright. For Dr. Cartwright the principal amount on the new note was $267,085, matures on February 18, 2023, and will accrue interest at a rate of 6%. For Dr. Faupel the principal amount on the new note was $153,178, matures on February 18, 2023, and will accrue interest at a rate of 6%. On February 19, 2021, the Company exchanged $100,000 and $85,000 of long-term debt for Dr. Cartwright and Dr. Faupel in exchange for 100 and 85 shares of Series F-2 Preferred Stock, respectively. The table below summarizes the detail of the exchange agreement: For Dr. Faupel: Salary $ 134 Bonus 20 Vacation 95 Interest on compensation 67 Loans to Company 196 Interest on loans 149 Total outstanding prior to exchange 661 Amount forgiven (454 ) Total Interest accrued through December 31, 2020 29 Balance outstanding at December 31, 2020 $ 236 Exchange for Series F-2 Preferred Stock (85 ) Interest accrued through September 30, 2021 8 Balance outstanding at September 30, 2021 $ 159 For Dr.Cartwright Salary $ 337 Bonus 675 Loans to Company 528 Interest on loans 81 Total outstanding prior to exchange 1,621 Amount forgiven (1,302 ) Total Interest accrued through December 31, 2020 45 Balance outstanding at December 31, 2020 $ 364 Exchange for Series F-2 Preferred Stock (100 ) Interest accrued through September 30, 2021 13 Balance outstanding at September 30, 2021 $ 277 On March 22, 2021, the Company entered into an exchange agreement with Richard Fowler. As of December 31, 2020, the Company owed Mr. Fowler $546,214 ($412,624 in deferred salary and $133,590 in accrued interest). The Company exchanged $50,000 of the amount owed of $546,214 for 50 share of Series F-2 Preferred Shares (convertible into 200,000 common stock shares), and a $150,000 unsecured note. The note accrues interest at the rate of 6% (18% in the event of default) beginning on March 22, 2022 and be payable in monthly installments of $3,580 for four years, with the first payment being due on March 15, 2022. The effective interest rate of the note is 6.18%. Mr. Fowler forgave $86,554 and may forgive up to $259,661 if the Company complies with the repayment plan described above. Mr. Fowler also has a short-term note for $26,400 and $18,718 in accrued interest. Future debt obligations which are recorded in the Long-term debt-related parties includes: $271,000, $158,000 and $150,000 for a total of $579,000 for Dr. Cartwright, Dr. Faupel, and Mr. Fowler, respectively. Future debt obligations at September 30, 2021 for debt owed to related parties is as follows: Year Amount 2021 $ - 2022 30 2023 457 2024 39 2025 41 Thereafter 3 Total $ 570 Small Business Administration Loan On May 4, 2020, the Company received a loan from the Small Business Administration (SBA) pursuant to the Paycheck Protection Program (PPP) as part of the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) in the amount of $50,184. The loan bears interest at a rate of 1.00%, and matures in 24 months, with the principal and interest payments being deferred until the date of forgiveness with interest accruing, then converting to monthly principal and interest payments, at the interest rate provided herein, for the remaining eighteen (18) months. Lender will apply each payment first to pay interest accrued to the day Lender received the payment, then to bring principal current, and will apply any remaining balance to reduce principal. Payments must be made on the same day as the date of this Note in the months they are due. Lender shall adjust payments at least annually as needed to amortize principal over the remaining term of the Note. Under the provisions of the PPP, the loan amounts will be forgiven as long as: the loan proceeds are used to cover payroll costs, and most mortgage interest, rent, and utility costs over a 24 week period after the loan is made; and employee and compensation levels are maintained. In addition, payroll costs are capped at $100,000 on an annualized basis for each employee. Not more than 40% of the forgiven amount may be for non-payroll costs. As of September 30, 2021 and December 31, 2020, the outstanding balance was $17,837 (this amount is recorded in current portion of long-term debt) and $50,477, including $331 and $293 in accrued interest, respectively. During the nine month period ended September 30, 2021, the Company was notified that the application for loan forgiveness was approved in the amount of $23,742 in principal and $234 in interest. 10% Senior Unsecured Convertible Debenture On May 17, 2021, the Company issued 10% Senior Unsecured convertible debentures to investors, which mature on May 17, 2024 (the “Maturity Date”). The Company subscribed $1,130,000 of the $1,000 convertible debentures. The terms of the debentures are as follows: 1) the principal amount of some or all of the convertible debentures and accrued interest are convertible into common stock shares at the holder’s option, at a price of $0.50 per common stock share (the “conversion price”), subject to adjustment in certain events, at any time prior to maturity date; 2) upon successful uplist to a U.S. National Exchange, the note will automatically convert into the uplisting financing; 3) each debenture unit will have a right to 1,000 warrants for common stock shares, warrants have an exercise price of $0.80 and an expiration date of May 17, 2023; 4) if a Change of Control (as defined in the Convertible Debenture Certificate) occurs prior to the Maturity Date, unless the holder elects in writing to convert the Convertible Debentures into common shares, the Company will repay in cash upon the closing of such Change of Control all outstanding principal and accrued interest under each Convertible Debenture plus a Change of Control premium equal to an additional 3% of the outstanding principal sum under such Convertible Debenture. Prior to the closing of an Change of Control, in lieu of repayment as set forth in the preceding sentence, the holder has the right to elect in writing to convert, effective immediately prior to the effective date of such Change of Control, all outstanding principal and accrued Interest under the Convertible Debentures into common shares at the Conversion Price; 5) Subject to a holder’s option of electing conversion prior to the Redemption Date (as such term is defined below), on or after the date that is 24 months from the Closing Date if the daily volume weighted average trading price of the common shares is $1.50 per common share or more for each trading day over a 30 consecutive trading day period, the Company may, at any time (the “Redemption Date”), at its option, redeem all, or any portion of the Convertible Debentures for either: (i) a cash payment (in the form of a certified cheque or bank draft) that is equal to all outstanding principal and accrued interest under each Convertible Debenture up to the Redemption Date; or (ii) by issuing and delivering common shares to the holders of Convertible Debentures at a deemed price of US$0.50 per common share that is equal to all outstanding principal and accrued interest under each Convertible Debenture up to the Redemption Date, or any combination of (i) or (ii), upon not less than 30 days and not more than 60 days prior written notice in the manner provided in the Debenture Certificate, to the holder of Convertible Debentures. At September 30, 2021, the balance due on the 10% Senior Secured Convertible Debenture was $1,130,000 and accrued interest of $43,341. At September 30, 2021, the Company had also recorded a bond payable discount of $266,413 and had also unamortized debt issuance costs of $76,320, for a net balance of $787,267.

INCOME (LOSS) PER COMMON SHARE

INCOME (LOSS) PER COMMON SHARE	9 Months Ended
	Sep. 30, 2021
INCOME (LOSS) PER COMMON SHARE
12. INCOME (LOSS) PER COMMON SHARE	12. INCOME (LOSS) PER COMMON SHARE Basic net income (loss) per share attributable to common stockholders, amounts are computed by dividing the net income (loss) plus preferred stock dividends and deemed dividends on preferred stock by the weighted average number of shares outstanding during the year. Diluted net income (loss) per share attributable to common stockholders amounts are computed by dividing the net income (loss) plus preferred stock dividends, deemed dividends on preferred stock, after-tax interest on convertible debt and convertible dividends by the weighted average number of shares outstanding during the year, plus Series C, Series D, Series E, Series F and Series F-2 convertible preferred stock, Series G preferred stock, convertible debt, convertible preferred dividends and warrants convertible into common stock shares. The following table sets forth pertinent data relating to the computation of basic and diluted net loss per share attributable to common shareholders (in thousands, except for per-share data): September 30, 2021 2020 Net loss (1,922 ) (2,520 ) Basic weighted average number of shares outstanding 13,291 9,985 Net loss per share (basic) (0.14 ) (0.25 ) Diluted weighted average number of shares outstanding 13,291 9,985 Net loss per share (diluted) (0.14 ) (0.25 ) Dilutive equity instruments (number of equivalent units): Stock options 2,252 - Preferred stock 17,837 - Convertible debt 908 59,179 Warrants 16,979 8,048 Total Dilutive instruments 37,976 67,227 For period of net loss, basic and diluted earnings per share are the same as the assumed exercise of warrants and the conversion of convertible debt are anti-dilutive. Troubled Debt Restructuring As provided in the preceding footnotes, several transactions met the basic criteria for troubled debt, which are that the borrower is troubled, i.e., they are having financial difficulties, and a concession is granted by the creditor. Due to the Company being past due or in default on several of its loans, the debt is considered troubled debt. As of September 30, 2021, the troubled debt restructuring in total would have decreased the net loss by $85,000 and causing the per share calculation to change from .14 to .15 net loss per share.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Sep. 30, 2021
SUBSEQUENT EVENTS
13. SUBSEQUENT EVENTS	13. SUBSEQUENT EVENTS The Company had no material reportable events subsequent to September 30, 2021.

SIGNIFICANT ACCOUNTING POLICI_2

SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Sep. 30, 2021
SIGNIFICANT ACCOUNTING POLICIES
Use of Estimates	The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant areas where estimates are used include the allowance for doubtful accounts, inventory valuation and input variables for Black-Scholes, Monte Carlo simulations and binomial calculations. The Company uses the Monte Carlo simulations and binomial calculations in the calculation of the fair value of the warrant liabilities and the valuation of embedded conversion options and freestanding warrants.
Accounting Standards Update	FASB ASU 2021-04, “ Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options” – FASB ASU NO. 2020-06, “Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity” FASB ASU NO. 2019-12, “ Simplifying the Accounting for Income Taxes A variety of proposed or otherwise potential accounting standards are currently under consideration by standard-setting organizations and certain regulatory agencies. Because of the tentative and preliminary nature of such proposed standards, management has not yet determined the effect, if any that the implementation of such proposed standards would have on the Company’s consolidated financial statements.
Cash Equivalents	The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be a cash equivalent.
Accounts Receivable	The Company performs periodic credit evaluations of its distributors’ financial conditions and generally does not require collateral. The Company reviews all outstanding accounts receivable for collectability on a quarterly basis. An allowance for doubtful accounts is recorded for any amounts deemed uncollectable. Uncollectibility is determined based on the determination that a distributor will not be able to make payment and the time frame has exceeded one year. The Company does not accrue interest receivables on past due accounts receivable.
Concentrations of Credit Risk	The Company, from time to time during the years covered by these consolidated financial statements, may have bank balances in excess of its insured limits. Management has deemed this a normal business risk.
Inventory Valuation	All inventories are stated at lower of cost or net realizable value, with cost determined substantially on a “first-in, first-out” basis. Selling, general, and administrative expenses are not inventoried, but are charged to expense when incurred. As of September 30, 2021 and December 31, 2020, our inventories were as follows: (in thousands) September 30, December 31, 2021 2020 Raw materials $ 1,256 $ 1,276 Work-in-progress 86 80 Finished goods 33 7 Inventory reserve (785 ) (758 ) Total inventory $ 590 $ 605 The company periodically reviews the value of items in inventory and provides write-downs or write-offs of inventory based on its assessment of market conditions. Write-downs and write-offs are charged to cost of goods sold.
Property and Equipment	Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over estimated useful lives of three to seven years. Leasehold improvements are amortized at the shorter of the useful life of the asset or the remaining lease term. Depreciation and amortization expense are included in general and administrative expense on the statement of operations. Expenditures for repairs and maintenance are expensed as incurred. Property and equipment are summarized as follows at September 30, 2021 and December 31, 2020: (in thousands) September 30, December 31, 2021 2020 Equipment $ 1,052 $ 1,042 Software 652 652 Furniture and fixtures 41 41 Leasehold improvements 12 12 Subtotal 1,757 1,747 Less accumulated depreciation (1,746 ) (1,746 ) Property, equipment and leasehold improvements, net $ 11 $ 1 During the nine months ended September 30, 2021 and year ended December 31, 2020, the Company disposed of approximately nil and $647,000 of property and equipment that was fully depreciated, respectively. Depreciation expense related to property and equipment for the nine months ended September 30, 2021 and 2020 was not material.
Debt Issuance Costs	Debt issuance costs are capitalized and amortized over the term of the associated debt. Debt issuance costs are presented in the balance sheet as a direct deduction from the carrying amount of the debt liability consistent with the debt discount.
Patent Costs (Principally Legal Fees)	Costs incurred in filing, prosecuting, and maintaining patents are recurring, and expensed as incurred. Maintaining patents are expensed as incurred as the Company has not yet received U.S. FDA approval and recovery of these costs is uncertain. Such costs aggregated to approximately $14,800 and $17,000 for the nine months ended September 30, 2021 and 2020, respectively.
Leases	A lease provides the lessee the right to control the use of an identified asset for a period of time in exchange for consideration. Right-of-use assets represent the Company’s right to use an underlying asset for the lease term and operating lease liabilities represent the Company’s obligation to make lease payments arising from the lease. The Company determines if an arrangement is a lease at inception. Right-of-use assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. Where an operating lease contains extension options that the Company is reasonably certain to exercise, the extension period is included in the calculation of the right-of-use assets and lease liabilities. The discount rate used to determine the commencement date present value of lease payments is the interest rate implicit in the lease, or when that is not readily determinable, the Company utilizes its secured borrowing rate. Right-of-use assets include any lease payments required to be made prior to commencement and exclude lease incentives. Both right-of-use assets and lease liabilities exclude variable payments not based on an index or rate, which are treated as period costs. The Company’s lease agreements do not contain significant residual value guarantees, restrictions or covenants. See Note 7 – Commitments and Contingencies.
Accrued Liabilities	Accrued liabilities as of September 30, 2021 and December 31, 2020 are summarized as follows: (in thousands) September 30, December 31, Compensation $ 745 $ 1,094 Professional fees 36 83 Interest 211 1,517 Vacation 44 34 Preferred dividends 298 202 Other accrued expenses 46 65 Total $ 1,380 $ 2,995
Subscription Receivables	Cash received from investors for common stock shares that has not completed processing is recorded as a liability to subscription receivables.
Revenue Recognition	ASC 606, Revenue from Contracts with Customers, establishes a single and comprehensive framework which sets out how much revenue is to be recognized, and when. The core principle is that a vendor should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the vendor expects to be entitled in exchange for those goods or services. Revenue will now be recognized by a vendor when control over the goods or services is transferred to the customer. In contrast, revenue-based revenue recognition around an analysis of the transfer of risks and rewards; this now forms one of a number of criteria that are assessed in determining whether control has been transferred. The application of the core principle in ASC 606 is carried out in five steps: · Step 1 – Identify the contract with a customer: a contract is defined as an agreement (including oral and implied), between two or more parties, that creates enforceable rights and obligations and sets out the criteria for each of those rights and obligations. The contract needs to have commercial substance and it is probable that the entity will collect the consideration to which it will be entitled. · Step 2 – Identify the performance obligations in the contract: a performance obligation in a contract is a promise (including implicit) to transfer a good or service to the customer. Each performance obligation should be capable of being distinct and is separately identifiable in the contract. · Step 3 – Determine the transaction price: transaction price is the amount of consideration that the entity can be entitled to, in exchange for transferring the promised goods and services to a customer, excluding amounts collected on behalf of third parties. · Step 4 – Allocate the transaction price to the performance obligations in the contract: for a contract that has more than one performance obligation, the entity will allocate the transaction price to each performance obligation separately, in exchange for satisfying each performance obligation. The acceptable methods of allocating the transaction price include adjusted market assessment approach, expected cost plus a margin approach, and the residual approach in limited circumstances. Discounts given should be allocated proportionately to all performance obligations unless certain criteria are met and reallocation of changes in standalone selling prices after inception is not permitted. · Step 5 – Recognize revenue as and when the entity satisfies a performance obligation: the entity should recognize revenue at a point in time, except if it meets any of the three criteria, which will require recognition of revenue over time: the entity’s performance creates or enhances an asset controlled by the customer, the customer simultaneously receives and consumes the benefit of the entity’s performance as the entity performs, and the entity does not create an asset that has an alternative use to the entity and the entity has the right to be paid for performance to date. The Company did not recognize material revenues during the nine-month periods ended September 30, 2021 or 2020. The Company’s revenues do not require significant estimates or judgments. The Company is not party to contracts that include multiple performance obligations or material variable consideration. Contract Balances The Company defers payments received as revenue until earned based on the related contracts and applying ASC 606 as required. As of September 30, 2021, and December 31, 2020, the Company had $278,000 and $42,000 in deferred revenue, respectively.
Significant Distributors	As of September 30, 2021, accounts receivable outstanding was $149,000, the outstanding amount was netted against a $126,000 allowance, leaving a balance of $24,000 which was from one distributor. As of December 31, 2020, accounts receivable outstanding was $150,000, the outstanding amount was netted against a $126,000 allowance, leaving a balance of $24,000 which was from one distributor.
Research and Development	Research and development expenses consist of expenditures for research conducted by the Company and payments made under contracts with consultants or other outside parties and costs associated with internal and contracted clinical trials. All research and development costs are expensed as incurred.
Income Taxes	The provision for income taxes is determined in accordance with ASC 740, “ Income Taxes The Company has filed its 2020 federal and state corporate tax returns. The Company has entered into an agreed upon payment plan with the IRS for delinquent payroll taxes. The Company has an established payment arrangement for its delinquent state income taxes with the State of Georgia. Although the Company has been experiencing recurring losses, it is obligated to file tax returns for compliance with IRS regulations and that of applicable state jurisdictions. At December 31, 2020, the Company has approximately $61.6 million of net operating losses carryforward available. This net operating loss will be eligible to be carried forward for tax purposes at federal and applicable states level. A full valuation allowance has been recorded related the deferred tax assets generated from the net operating losses. The Company recognizes uncertain tax positions based on a benefit recognition model. Provided that the tax position is deemed more likely than not of being sustained, the Company recognizes the largest amount of tax benefit that is greater than 50.0% likely of being ultimately realized upon settlement. The tax position is derecognized when it is no longer more likely than not of being sustained. The Company classifies income tax related interest and penalties as interest expense and selling, general and administrative expense, respectively, on the consolidated statements of operations.
Warrants	The Company has issued warrants, which allow the warrant holder to purchase one share of stock at a specified price for a specified period of time. The Company records equity instruments including warrants based on the fair value at the date of issue. The fair value of warrants classified as equity instruments at the date of issuance is estimated using the Black-Scholes Model. The fair value of warrants classified as liabilities at the date of issuance is estimated using the Monte Carlo Simulation or Binomial model.
Stock Based Compensation	The Company accounts for its stock-based awards in accordance with ASC Subtopic 718, “ Compensation – Stock Compensation The Black-Scholes option pricing model requires the input of certain assumptions that require the Company’s judgment, including the expected term and the expected stock price volatility of the underlying stock. The assumptions used in calculating the fair value of stock-based compensation represent management’s best estimates, but these estimates involve inherent uncertainties and the application of judgment. As a result, if factors change resulting in the use of different assumptions, stock-based compensation expense could be materially different in the future.
Beneficial Conversion Features of Convertible Securities	The Company has adopted the provisions of ASU 2017-11 to account for the down round features of warrants issued with private placements effective as of January 1, 2020. In doing so, warrants with a down round feature previously treated as derivative liabilities in the consolidated balance sheet and measured at fair value are henceforth treated as equity, with no adjustment for changes in fair value at each reporting period. Previously, the Company accounted for conversion options embedded in convertible notes in accordance with ASC 815. ASC 815 generally requires companies to bifurcate conversion options embedded in convertible notes from their host instruments and to account for them as free-standing derivative financial instruments. ASC 815 provides for an exception to this rule when convertible notes, as host instruments, are deemed to be conventional, as defined by ASC 815-40. The Company accounts for convertible notes deemed conventional and conversion options embedded in non-conventional convertible notes which qualify as equity under ASC 815, in accordance with the provisions of ASC 470-20, which provides guidance on accounting for convertible securities with beneficial conversion features. Accordingly, the Company records, as a discount to convertible notes, the intrinsic value of such conversion options based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt. Conversion options that are not bifurcated as a derivative pursuant to ASC 815 and not accounted for as a separate equity component under the cash conversion guidance are evaluated to determine whether they are beneficial to the investor at inception (a beneficial conversion feature) or may become beneficial in the future due to potential adjustments. The beneficial conversion feature guidance in ASC 470-20 applies to convertible stock as well as convertible debt which are outside the scope of ASC 815. A beneficial conversion feature is defined as a nondetachable conversion feature that is in the money at the commitment date. The beneficial conversion feature guidance requires recognition of the conversion option’s in-the-money portion, the intrinsic value of the option, in equity, with an offsetting reduction to the carrying amount of the instrument. The resulting discount is amortized as a dividend over either the life of the instrument, if a stated maturity date exists, or to the earliest conversion date, if there is no stated maturity date. If the earliest conversion date is immediately upon issuance, the dividend must be recognized at inception. When there is a subsequent change to the conversion ratio based on a future occurrence, the new conversion price may trigger the recognition of an additional beneficial conversion feature on occurrence. The Company also adopted ASU No. 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (ASU 2020-06), which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity’s own equity. Among other changes, ASU 2020-06 removes from U.S. GAAP the liability and equity separation model for convertible instruments with a cash conversion feature, and as a result, after adoption, entities will no longer separately present in equity an embedded conversion feature for such debt.
Derivatives	The Company reviews the terms of convertible debt issued to determine whether there are embedded derivative instruments, including embedded conversion options, which are required to be bifurcated and accounted for separately as derivative financial instruments. In circumstances where the host instrument contains more than one embedded derivative instrument, including the conversion option, that is required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument. Bifurcated embedded derivatives are initially recorded at fair value and are then revalued at each reporting date with changes in the fair value reported as non-operating income or expense. When the equity or convertible debt instruments contain embedded derivative instruments that are to be bifurcated and accounted for as liabilities, the total proceeds received are first allocated to the fair value of all the bifurcated derivative instruments. The remaining proceeds, if any, are then allocated to the host instruments themselves, usually resulting in those instruments being recorded at a discount from their face value. The discount from the face value of the convertible debt, together with the stated interest on the instrument, is amortized over the life of the instrument through periodic charges to interest expense.

SIGNIFICANT ACCOUNTING POLICI_3

SIGNIFICANT ACCOUNTING POLICIES (Tables)	9 Months Ended
	Sep. 30, 2021
SIGNIFICANT ACCOUNTING POLICIES
Inventory valuation	(in thousands) September 30, December 31, 2021 2020 Raw materials $ 1,256 $ 1,276 Work-in-progress 86 80 Finished goods 33 7 Inventory reserve (785 ) (758 ) Total inventory $ 590 $ 605
Property and equipment	(in thousands) September 30, December 31, 2021 2020 Equipment $ 1,052 $ 1,042 Software 652 652 Furniture and fixtures 41 41 Leasehold improvements 12 12 Subtotal 1,757 1,747 Less accumulated depreciation (1,746 ) (1,746 ) Property, equipment and leasehold improvements, net $ 11 $ 1
Accrued liabilities	(in thousands) September 30, December 31, Compensation $ 745 $ 1,094 Professional fees 36 83 Interest 211 1,517 Vacation 44 34 Preferred dividends 298 202 Other accrued expenses 46 65 Total $ 1,380 $ 2,995

FAIR VALUE OF FINANCIAL INSTR_2

FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)	9 Months Ended
	Sep. 30, 2021
FAIR VALUE OF FINANCIAL INSTRUMENTS
Schedule fo fair value for liabilities measured on a recurring basis	Fair Value at September 30, 2021 Level 1 Level 2 Level 3 Total Derivative liability/bifurcated conversion option in connection with Auctus $400,000 loan on December 17, 2019 $ - $ - $ (30 ) $ (30 ) Total long-term liabilities at fair value $ - $ - $ (30 ) $ (30 ) Fair Value at December 31, 2020 Level 1 Level 2 Level 3 Total Warrants issued in connection with Senior Secured Debt $ $ (2,203 ) $ (2,203 ) Derivative liability/bifurcated conversion option in connection with Auctus $400,000 loan on December 17, 2019 - - (25 ) (25 ) Total long-term liabilities at fair value $ - $ - $ (2,228 ) $ (2,228 )
Summary of changes to Level 3 instruments	(in thousands) Senior Secured Debt Derivative Total Balance, December 31, 2020 $ (2,203 ) $ (25 ) $ (2,228 ) Change in the terms of warrants previously recorded as a liability and now reclassified to equity 1,755 - 1,755 Change in value due to warrants expiring during the year 448 - 448 Extinguishment of derivative liability due to payoff of $700,000 loan to Auctus - 84 - Change in fair value during the year - (89 ) (89 ) Balance, September 30, 2021 $ - $ (30 ) $ (114 )

STOCKHOLDERS' DEFICIT (Tables)

STOCKHOLDERS' DEFICIT (Tables)	9 Months Ended
	Sep. 30, 2021
STOCKHOLDERS' DEFICIT:
Common stock issued	Number of Shares Shares issued for payment of Series D dividends 83,065 Shares issued for payment of Series E dividends 288,262 Shares issued for payment of finder fee 98,000 Issued during the nine months ended September 30, 2021 469,327 Summary table of common stock share transactions: Balance at December 31, 2020 13,138,282 Issued in 2021 469,327 Balance at September 30, 2021 13,607,609
Outstanding warrants	Warrants Weighted-Average Exercise Price Per Share Outstanding, January 1, 2021 28,324,275 $ 0.25 Warrants granted 3,504,300 $ 0.48 Warrants cancelled/expired (1,729,662 ) $ 0.04 Outstanding, September 30, 2021 30,098,913 $ 0.29

STOCK OPTIONS (Tables)

STOCK OPTIONS (Tables)	9 Months Ended
	Sep. 30, 2021
STOCK OPTIONS
Stock options granted	Number of Shares Weighted-Average Exercise Price Per Share Weighted-Average Remaining Contractual Life Aggregate Intrinsic Value of In-the-Money Options Options outstanding as of January 1, 2021 1,800,000 $ 0.49 Options granted 25,000 $ 0.48 Options exercised - $ - Options forfeited (167,614 ) $ 0.48 Options expired - $ - Options outstanding as of September 30, 2021 1,657,386 $ 0.49 8.8 years $ 127 Options exercisable as of September 30, 2021 1,009,705 $ 0.49 8.8 years $ 71
Stock option activity	September 30, September 30, 2021 2020 Expected term (years) 10 years 10 years Volatility 153.1 % 153.12 % Risk-free interest rate 0.98 % 0.98 % Dividend yield 0.00 % 0.00 %

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	9 Months Ended
	Sep. 30, 2021
COMMITMENTS AND CONTINGENCIES (Note 7)
Future minimum rental payments under non-cancellable operating leases	(in thousands) Operating Leases 2021 $ 26 2022 108 2023 112 2024 115 2025 118 Thereafter 50 Total future lease payments 529 Less: discount (122 ) Total lease liabilities $ 407
Operating lease right-of-use assets and lease liabilities	(in thousands) Nine Months Ended September 30, 2021 Operating lease right-of-use assets $ 388 Operating lease liabilities $ 407
Weighted-average remaining lease term and discount rate used in the calculation of operating lease right-of-use assets and lease liabilities	Nine Months Ended September 30, 2021 Weighted average remaining lease term (years) 4.5 Weighted average discount rate 11.4 %

NOTES PAYABLE (Tables)

NOTES PAYABLE (Tables)	9 Months Ended
	Sep. 30, 2021
NOTES PAYABLE
Notes payable in default, including related parties	September 30, 2021 December 31, 2020 Mr. Mermelstein $ - $ 285 Dr. Cartwright - 1 Mr. Fowler - 26 GPB - 17 Notes payable in default $ - $ 329
Short-term notes payable, including related parties	September 30, 2021 December 31, 2020 Dr. Cartwright $ 37 $ 46 Dr. Faulpel - 5 Mr. Fowler 13 - Premium Finance (insurance) 83 45 Short-term notes payable $ 133 $ 96

SHORT-TERM CONVERTIBLE DEBT (Ta

SHORT-TERM CONVERTIBLE DEBT (Tables)	9 Months Ended
	Sep. 30, 2021
SHORT-TERM CONVERTIBLE DEBT
Convertible notes payable	September 30, 2021 December 31, 2020 Auctus Tranche 1 - 700 Auctus Tranche 2 $ 400 $ 400 Auctus prepayment penalty 350 - Auctus (March 31, 2020 Note) 161 113 Debt discount and issuance costs to be amortizaed (22 ) (262 ) Convertible notes payable - short-term $ 889 $ 951

CONVERTIBLE DEBT (Tables)

CONVERTIBLE DEBT (Tables)	9 Months Ended
	Sep. 30, 2021
SHORT-TERM CONVERTIBLE DEBT
Convertible notes in default	September 30, 2021 December 31, 2020 GBP $ - $ 1,709 GHS - 181 Auctus - 40 Convertible notes payable $ - $ 1,930

LONG TERM DEBT (Tables)

LONG TERM DEBT (Tables)	9 Months Ended
	Sep. 30, 2021
LONG TERM DEBT
Long-term debt, related parties	For Dr. Faupel: Salary $ 134 Bonus 20 Vacation 95 Interest on compensation 67 Loans to Company 196 Interest on loans 149 Total outstanding prior to exchange 661 Amount forgiven (454 ) Total Interest accrued through December 31, 2020 29 Balance outstanding at December 31, 2020 $ 236 Exchange for Series F-2 Preferred Stock (85 ) Interest accrued through September 30, 2021 8 Balance outstanding at September 30, 2021 $ 159 For Dr.Cartwright Salary $ 337 Bonus 675 Loans to Company 528 Interest on loans 81 Total outstanding prior to exchange 1,621 Amount forgiven (1,302 ) Total Interest accrued through December 31, 2020 45 Balance outstanding at December 31, 2020 $ 364 Exchange for Series F-2 Preferred Stock (100 ) Interest accrued through September 30, 2021 13 Balance outstanding at September 30, 2021 $ 277
Long-term debt, related parties debt obligations	Year Amount 2021 $ - 2022 30 2023 457 2024 39 2025 41 Thereafter 3 Total $ 570

INCOME (LOSS) PER COMMON SHARE

INCOME (LOSS) PER COMMON SHARE (Tables)	9 Months Ended
	Sep. 30, 2021
INCOME (LOSS) PER COMMON SHARE
Earnings per share	September 30, 2021 2020 Net loss (1,922 ) (2,520 ) Basic weighted average number of shares outstanding 13,291 9,985 Net loss per share (basic) (0.14 ) (0.25 ) Diluted weighted average number of shares outstanding 13,291 9,985 Net loss per share (diluted) (0.14 ) (0.25 ) Dilutive equity instruments (number of equivalent units): Stock options 2,252 - Preferred stock 17,837 - Convertible debt 908 59,179 Warrants 16,979 8,048 Total Dilutive instruments 37,976 67,227

ORGANIZATION, BACKGROUND, AND_2

ORGANIZATION, BACKGROUND, AND BASIS OF PRESENTATION (Details Narrative) - USD ($) $ / shares in Units, shares in Millions	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2021
Working capital	$ (3,700,000)
Accumulated deficit	141,900,000
Total stockholders' deficits	$ 5,100,000
Warrants [Member] | Minimum
Warrants exercise price per share	$ 0.15
Warrants [Member] | Maximum
Warrants exercise price per share	$ 0.80
Warrants [Member] | Exchange Agreement With GPB [Member]
Warrants exercisable for common stock outstanding	30.1
Proceeds from exercise of warrants	$ 5,700,000
Subsequent Event | 10% Convertible Debentures
Proceeds from sale of stocks		$ 1,100,000
Series F, Series F-2 and G Preferred Stock | Subsequent Event
Proceeds from sale of stocks		$ 3,200,000

SIGNIFICANT ACCOUNTING POLICI_4

SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
SIGNIFICANT ACCOUNTING POLICIES
Raw materials	$ 1,256	$ 1,276
Work in process	86	80
Finished goods	33	7
Inventory reserve	(785)	(758)
Total	$ 590	$ 605

SIGNIFICANT ACCOUNTING POLICI_5

SIGNIFICANT ACCOUNTING POLICIES (Details 1) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Property and equipment, gross	$ 1,757	$ 1,747
Less accumulated depreciation and amortization	(1,746)	(1,746)
Property and equipment, net	11	1
Furniture and Fixtures
Property and equipment, gross	41	41
Equipment
Property and equipment, gross	1,052	1,042
Software
Property and equipment, gross	652	652
Leasehold Improvement
Property and equipment, gross	$ 12	$ 12

SIGNIFICANT ACCOUNTING POLICI_6

SIGNIFICANT ACCOUNTING POLICIES (Details 2) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
SIGNIFICANT ACCOUNTING POLICIES
Compensation	$ 745	$ 1,094
Professional fees	36	83
Interest	211	1,517
Vacation	44	34
Preferred dividends	298	202
Other accrued expenses	46	65
Total	$ 1,380	$ 2,995

SIGNIFICANT ACCOUNTING POLICI_7

SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
SIGNIFICANT ACCOUNTING POLICIES
Disposal of property and equipment	$ 647,000,000		$ 647,000,000
Patent costs	14,800,000	$ 17,000,000
Accounts receivable outstanding	149,000,000		150,000,000
Outstanding amount balance	24,000		24,000
Accounts receivable, net of allowance	126,000,000		126,000,000
Deferred revenue	$ 278,000,000		42,000,000
Net operating loss carry forward			$ 61,600,000

FAIR VALUE OF FINANCIAL INSTR_3

FAIR VALUE OF FINANCIAL INSTRUMENTS (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Derivative liability	$ (30,000)	$ (2,228,000)
Auctus Loan
Derivative liability	(30,000)	(25,000)
Senior Secured Debt
Derivative liability		(2,203,000)
Level 1
Derivative liability	0	0
Level 1 | Auctus Loan
Derivative liability	0	0
Level 1 | Senior Secured Debt
Derivative liability		0
Level 2
Derivative liability	0	0
Level 2 | Auctus Loan
Derivative liability	0	0
Level 2 | Senior Secured Debt
Derivative liability		0
Level 3
Derivative liability	(30,000)	(2,228,000)
Level 3 | Auctus Loan
Derivative liability	$ (30,000)	(25,000)
Level 3 | Senior Secured Debt
Derivative liability		$ (2,203,000)

FAIR VALUE OF FINANCIAL INSTR_4

FAIR VALUE OF FINANCIAL INSTRUMENTS (Details 1) - Level 3	9 Months Ended
	Sep. 30, 2021USD ($)
Beginning Balance, Warrants	$ (2,228)
Change in the terms of warrants previously recorded as a liability and now reclassified to equity	1,755,000
Change in value due to warrants expiring during the year	448,000
Extinguishment of derivative liability due to payoff of $700,000 loan to Auctus	0
Change in fair value during the year	(89,000)
Ending Balance, Warrants	(114)
Senior Secured Debt
Beginning Balance, Warrants	(2,203)
Change in the terms of warrants previously recorded as a liability and now reclassified to equity	1,755,000
Change in value due to warrants expiring during the year	448,000
Extinguishment of derivative liability due to payoff of $700,000 loan to Auctus	0
Change in fair value during the year	0
Ending Balance, Warrants	0
Derivative
Beginning Balance, Warrants	(25)
Change in the terms of warrants previously recorded as a liability and now reclassified to equity	0
Change in value due to warrants expiring during the year	0
Extinguishment of derivative liability due to payoff of $700,000 loan to Auctus	84
Change in fair value during the year	(89,000)
Ending Balance, Warrants	$ (30)

FAIR VALUE OF FINANCIAL INSTR_5

FAIR VALUE OF FINANCIAL INSTRUMENTS (Details Narrative) - USD ($)	1 Months Ended	9 Months Ended
	Dec. 17, 2017	Sep. 30, 2021
FAIR VALUE OF FINANCIAL INSTRUMENTS
Derivative liability/bifurcated conversion option in connection with auctus loan	$ 400,000	$ 1,100,000
Extinguishment of derivative liability due to payoff of loan to Auctus		700,000
Derivative liability		$ 400,000

STOCKHOLDERS DEFICIT (Details)

STOCKHOLDERS DEFICIT (Details)	9 Months Ended
	Sep. 30, 2021shares
STOCKHOLDERS' DEFICIT:
Shares issued for payment of Series D dividends	83,065
Shares issued for payment of Series E dividends	288,262
Shares issued for payment of finder fee	98,000
Issued during the nine months ended September 30, 2021	469,327
Balance, shares	13,138,282
Issued in 2021	469,327
Balance, shares	13,607,609

STOCKHOLDERS DEFICIT (Details 1

STOCKHOLDERS DEFICIT (Details 1)	9 Months Ended
	Sep. 30, 2021$ / sharesshares
Weighted-Average Exercise Price Per Share, outstanding, granted	$ 0.48
Weighted-Average Exercise Price Per Share, outstanding, cancelled/expired	$ 0.48
Warrants [Member]
Warrants outstanding, beginning | shares	28,324,275
Granted | shares	3,504,300
Canceled/expired | shares	(1,729,662)
Warrants outstanding, ending | shares	30,031,913
Weighted-Average Exercise Price Per Share, outstanding, beginning	$ 0.25
Weighted-Average Exercise Price Per Share, outstanding, granted	0.48
Weighted-Average Exercise Price Per Share, outstanding, cancelled/expired	0.04
Weighted-Average Exercise Price Per Share, outstanding, ending	$ 0.29

STOCKHOLDERS DEFICIT (Details N

STOCKHOLDERS DEFICIT (Details Narrative) - USD ($)	Jul. 08, 2021	Mar. 10, 2021	Jan. 08, 2020	Mar. 22, 2021	Feb. 28, 2021	Jan. 31, 2021	Aug. 31, 2018	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020	Mar. 31, 2021	Feb. 19, 2021	Jan. 08, 2021
Common stock, par value								$ 0.001		$ 0.001
Common stock, authorized public shares								3,000,000,000		3,000,000,000
Common stock, issued public shares								13,607,609		13,607,609
Preferred stock shares authorized								5,000,000
Preferred stock shares par value								$ 0.001
Issued during the six months ended June 30, 2021								469,327
Shares exchange								13,607,609		13,138,282	13,180,417
Common stock issued during period								98,000
Investments | Subsequent Event
Common stock, issued public shares									98,000
Total investment amount									$ 2,114,000
Warrants for common stock shares equity									643,700
Equity investments fee									$ 139,000
Warrants for common stock shares									1,130,000
Proceeds from debenture unit investments									$ 1,130,000
Debenture fee									$ 86,400
Debentures convertible into common stock shares									2,260,000
Dr. Faupel
Forgive repayment amount										$ 454,000
Short-term note								$ 159,000		236,000
Dr. Cartwright
Forgive repayment amount										1,302,000
Short-term note								277,000		$ 364,000
Debt Exchanges - 2020 | Ms. Rosenstock
Forgive repayment amount								$ 28,986
Debt Exchanges - 2021
Common stock, issued public shares								2,236		13,138,282
Debt													$ 1,500,000
Debt final payment													$ 750,000
Debt Exchanges - 2021 | Mr. Fowler
Preferred stock shares converts into common stock				200,000
Deferred salary				$ 412,624
Accrued interest				133,590
Total Compensation				546,214
Exchanged amount				50,000
Amount owed				546,214
Unsecured note				$ 150,000
Shares exchange				50
Accrues interest rate, percentage				6.00%
Monthly installments				$ 3,600
Monthly installments period term				4 years
Short-term note				$ 26,400
short-term note accrued interest				18,718
Debt Exchanges - 2021 | Mr. Fowler | Maximum
Forgive repayment amount				86,554
Debt Exchanges - 2021 | Mr. Blumberg
Shares exchange		88
Consulting fees		$ 88,000
Debt Exchanges - 2021 | Dr. Faupel
Shares exchange												100
Long-term debt												$ 100,000
Debt Exchanges - 2021 | Dr. Cartwright
Shares exchange												85
Long-term debt												$ 85,000
Series C Convertible Preferred Shares
Preferred stock shares authorized								9,000		9,000
Preferred stock shares par value								$ 0.001		$ 0.001
Preferred stock shares outstanding								300		300
Preferred stock shares designated								9,000
Conversion price per share								$ 0.50
Preferred stock shares converts into common stock							2,000	2,000		2,000
Total convertible of common stock shares							6,524,500	572,000
Convertible of common stock shares description								The conversion price will automatically adjust downward to 80% of the then-current market price of the Company’s common stock 15 trading days after any reverse stock split of the Company’s common stock, and 5 trading days after any conversions of the Company’s outstanding convertible debt. Holders of the Series C preferred stock are entitled to quarterly cumulative dividends at an annual rate of 12.0% until 42 months after the original issuance date.
Liquidation preference								$ 1,000
Preferred stock shares issued								300		300
Series C1 Convertible Preferred Shares
Preferred stock shares outstanding								1,050		1,050
Conversion price per share								$ 0.50		$ 0.50
Preferred stock shares converts into common stock								2,000		2,000
Total convertible of common stock shares								2,098,500		2,098,500
Preferred stock shares issued								1,050		1,050
Preferred stock shares surrendered								3,262,225
Shares outstanding								104,925		1,024,925
Series C2 Convertible Preferred Shares
Conversion price per share							$ 0.50	$ 0.50		$ 0.50
Total convertible of common stock shares								2,000		2,000
Preferred stock shares surrendered								326,225
Series F-2 Convertible Preferred Shares
Preferred stock shares authorized								5,000		5,000
Preferred stock shares par value								$ 0.001		$ 0.001
Preferred stock shares outstanding								3,300		0
Preferred stock shares designated								3,500
Preferred stock shares converts into common stock								4,000
Liquidation preference								$ 3,339
Convertible preferred stock description								Board designated 5,000 shares of preferred stock as Series F-2 Preferred Stock, 3,237 of which are issued and outstanding. During 2021, the Company entered into a Stock Purchase Agreement with certain accredited investors (“the Series F-2 Investors”). In total, for $678,000 the Company issued 678 shares of Series F-2 Preferred Stock. In addition, the Company exchanged outstanding debt of $2,559,000 for 2,559 shares of Series F-2 Preferred Stock. Each Series F-2 Preferred Stock is convertible into 4,000 common stock shares. The Series F-2 Preferred Stock will have cumulative dividends at the rate per share of 6% per annum. The stated value and liquidation preference on the Series F-2 Preferred Stock is $3,339. Below is a summary of the debt exchanges. On March 22, 2021, the Company exchanged $50,000 of the amount owed of $546,214 for 50 shares of Series F-2 Preferred Shares (convertible into 200,000 common stock shares), a $150,000 unsecured note and Mr. Fowler will remain on our health insurance plan. Mr. Fowler forgave $86,554 and may forgive up to $259,661 if the Company complies with the repayment plan.
Convertible preferred stock description 1								On March 22, 2021, the Company exchanged $50,000 of the amount owed of $546,214 for 50 shares of Series F-2 Preferred Shares (convertible into 200,000 common stock shares), a $150,000 unsecured note and Mr. Fowler will remain on our health insurance plan. Mr. Fowler forgave $86,554 and may forgive up to $259,661 if the Company complies with the repayment plan. Each share of Series F-2 Preferred is convertible, at any time for a period of 5 years after issuance, into that number of shares of Common Stock, determined by dividing the Stated Value by $0.25, subject to certain adjustments set forth in the Series F-2 Certificate of Designation (the “Series F-2 Conversion Price”). The conversion of Series F-2 Preferred is subject to a 4.99% beneficial ownership limitation, which may be increased to 9.99% at the election of the holders of the Series F-2 Preferred. If the average of the VWAPs (as defined in the Series F-2 Certificate of Designation) for any consecutive 5 trading day period (“Measurement Period”) exceeds 200% of the then Series F-2 Conversion Price and the average daily trading volume of the Common Stock on the primary trading market exceeds 1,000 shares per trading day during the Measurement Period (subject to adjustments), the Company may redeem the then outstanding Series F-2 Preferred, for cash in an amount equal to aggregate Stated Value then outstanding plus accrued but unpaid dividends.
Increased beneficial ownership percentage								9.99%
Preferred stock shares received								678,000
Outstanding debt								$ 2,559,000
Final payment			$ 750,000					750,000
Exchange agreement payment			$ 1,500,000
Dividends Paid Amount								$ 99,593
Forgive repayment amount				88,554
Preferred stock shares issued								3,300		0
Series F-2 Convertible Preferred Shares | Maximum
Forgive repayment amount				$ 259,661
Series F-2 Convertible Preferred Shares | Mr. Blumberg
Shares exchange		88
Consulting fees		$ 88,000
Series F-2 Convertible Preferred Shares | Dr. Faupel
Shares exchange												85
Long-term debt												$ 85,000
Series F-2 Convertible Preferred Shares | Dr. Cartwright
Shares exchange												100
Long-term debt												$ 100,000
Series G Convertible Preferred Shares
Preferred stock shares authorized								1,000,000		1,000,000
Preferred stock shares par value								$ 0.001		$ 0.001
Preferred stock shares outstanding								0		0
Convertible preferred stock description								uring January 2021, the Company finalized an investment by Power Up Lending Group Ltd. Power Up invested $78,500, net to the Company is $75,000, for 91,000 shares of Series G preferred stock with additional tranches of financing up to $925,000 in the aggregate over the terms of the Series G preferred stock. Series G will be non-voting on any matters requiring shareholder vote. The Series G Preferred Stock will have cumulative dividends at the rate per share of 8% per annum. Series G preferred stock by paying an amount equal to: (i) the number of shares of Series G preferred stock multiplied by then stated value (including accrued dividends); (ii) multiplied by the corresponding percentage as follows: Day 1-60, 105%; Day 61-90, 110%; Day 91-120, 115%; and Day 121-180, 122%. The variable conversion price will be the value equal to a discount of 19% off of the trading price; which is calculated as the average of the three lowest closing bid prices over the last fifteen trading days. The conversion of Series G Preferred is subject to a 4.99% beneficial ownership limitation, which may be increased to 9.99% at the election of the holder of the Series G Preferred.
Convertible preferred stock description 1								During February 2021, the Company finalized an investment by Power Up Lending Group Ltd. Power Up invested $53,500, net to the Company is $50,000, for 62,000 shares of Series G preferred stock with additional tranches of financing up to $925,000 in the aggregate over the terms of the Series G preferred stock. Series G will be non-voting on any matters requiring shareholder vote. The Series G Preferred Stock will have cumulative dividends at the rate per share of 8% per annum. Series G preferred stock by paying an amount equal to: (i) the number of shares of Series G preferred stock multiplied by then stated value (including accrued dividends); (ii) multiplied by the corresponding percentage as follows: Day 1-60, 105%; Day 61-90, 110%; Day 91-120, 115%; and Day 121-180, 122%. After the expiration of the 180 days following the issuance date, except for mandatory redemption, the Company shall have no right to redeem the Series G preferred stock. Mandatory redemption occurs within 24 months. In addition, if the Company does not redeem the Series G preferred stock then Power Up will have the option to convert to common stock shares. The variable conversion price will be the value equal to a discount of 19% off of the trading price; which is calculated as the average of the three lowest closing bid prices over the last fifteen trading days. The conversion of Series G Preferred is subject to a 4.99% beneficial ownership limitation, which may be increased to 9.99% at the election of the holder of the Series G Preferred. Due to the mandatory redemption feature of the Series G preferred stock, the total amount of proceeds of $125,000 was recorded as a liability. On June 4, 2021, the Company redeemed the January 2021 investment of $75,000 for $114,597, this $39,597 difference was recorded as interest expense. As of June 30, 2021, the amount outstanding was $50,000 and is presented as a liability. As of June 30, 2021, the Company has also accrued dividends of $1,915.
Preferred stock shares received									153,000
Preferred stock shares issued								0		0
Investment net									$ 132,000
Investment net									$ 125,000
Preferred stock redeemed									91,000
Series G Convertible Preferred Shares | Power Up Lending Group Ltd [Member]
Investment net					$ 53,500	$ 78,500
Additional Series G preferred stock shares, amount					50,000	75,000
Financing cost					$ 925,000	$ 925,000
Discounted rate					19.00%	19.00%
Redemption of february 2021 investment, amount	$ 78,094
Difference of interest expense	$ 28,094							$ 39,597
Conversion beneficial ownership limitation					4.99%	4.99%
Increased election holders					9.99%	9.99%
Cumulative dividends rate					8.00%	8.00%
Corresponding percentage Description					Day 1-60, 105%; Day 61-90, 110%; Day 91-120, 115%; and Day 121-180, 122%.	Day 1-60, 105%; Day 61-90, 110%; Day 91-120, 115%; and Day 121-180, 122%.
Additional Series G preferred stock shares					62,000
Net proceeds								125,000
Total investment amount								75,000
Outstanding amount								$ 50,000
Series D Preferred Shares
Common stock, issued public shares								1,526,000
Preferred stock shares designated								6,000
Conversion price per share								$ 0.25
Preferred stock shares converts into common stock								763
Liquidation preference								$ 763
Increased beneficial ownership percentage								9.99%
Preferred stock shares issued								763,000
Shares outstanding								763
Common stock warrants 1								1,526,000
Warrant exercise price per share								0.25
Common stock warrants								1,526,000
Common stock warrants exercise price 1								$ 0.75
Conversion of investor shares								3,000
Common stock issued during period								83,065
Preferred stock dividends accrued								$ 14,306
Common Stock primary trading shares exceed								1,000
Exceeds percentage								200.00%
Series E Preferred Shares
Preferred stock shares par value								$ 0.001
Preferred stock shares designated								5,000
Conversion price per share								$ 0.25
Liquidation preference								$ 1,736
Common Stock primary trading shares exceed								1,000
Exceeds percentage								200.00%
Preferred stock stated value								$ 1,000
Common stock shares issued for preferred stock dividends								288,262
Accrued dividends								$ 19,811
Increased election holder								9.99%
Conversion beneficial ownership limitation								4.99%
Maturity period								5 years
Series F and Series F-2 Preferred Shares
Preferred stock shares converts into common stock									4,000
Preferred stock shares received									2,114
Accrued Value								$ 136,667
Series F Preferred Shares
Preferred stock shares outstanding								1,436
Preferred stock shares designated								1,500
Conversion price per share								$ 0.25
Preferred stock shares converts into common stock								4,000		4,000
Liquidation preference								$ 1,436
Preferred stock shares issued								1,436
Common Stock primary trading shares exceed								1,000
Exceeds percentage								200.00%
Increased election holder								9.99%
Conversion beneficial ownership limitation								4.99%
Maturity period								5 years
Dividend amount								$ 44,199
Cumulative dividend rate								6.00%
Accredited investors								$ 1,436,000

STOCK OPTIONS (Details)

STOCK OPTIONS (Details)	9 Months Ended
	Sep. 30, 2021USD ($)$ / sharesshares
STOCK OPTIONS
Outstanding at beginning of year | shares	1,800,000
Options granted | shares	25,000
Options exercised | shares	0
Options forfeited | shares	(167,614)
Outstanding, end | shares	1,657,386
Number of shares exercisable | shares	1,009,705
Options outstanding weighted average exercise price, beginning | $ / shares	$ 0.49
Options granted weighted average exercise price | $ / shares	0.48
Options exercised weighted average exercise price | $ / shares	0
Options forfeited weighted average exercise price | $ / shares	0.48
Outstanding at end of the period | $ / shares	0.49
Weighted average exercise price per share exercisable | $ / shares	$ 0.49
Weighted average remaining contractual life outstanding	8 years 9 months 18 days
Weighted average remaining contractual life exercisable	8 years 9 months 18 days
Agrregate intrensic value outstanding | $	$ 127
Agrregate intrensic value exercisable | $	$ 71

STOCK OPTIONS (Details 1)

STOCK OPTIONS (Details 1)	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
STOCK OPTIONS
Expected term (years)	10 years	10 years
Volatility	153.10%	153.12%
Risk-free interest rate	0.98%	0.98%
Dividend yield	0.00%	0.00%

STOCK OPTION (Details Narrative

STOCK OPTION (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
STOCK OPTIONS
Unrecognized stock-based compensation expense	$ 312,693
Weighted-average fair value of awards granted	$ 0.47	$ 0.48
Stock options to employees and consultants term	10 years
Stock options granted outstanding common stock shares percentage	10.00%
Options granted exercisable term	4 years

COMMITMENTS AND CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES (Details 1) $ in Thousands	Sep. 30, 2021USD ($)
COMMITMENTS AND CONTINGENCIES (Note 7)
2021	$ 26
2022	108
2023	112
2024	115
2025	118
Thereafter	50
Total future lease payments	529
Less: discount	(122)
Total lease liabilities	$ (407)

COMMITMENTS AND CONTINGENCIES_3

COMMITMENTS AND CONTINGENCIES (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
COMMITMENTS AND CONTINGENCIES (Note 7)
Operating lease right-of-use assets	$ 388	$ 453
Total lease liabilities	$ 407

COMMITMENTS AND CONTINGENCIES_4

COMMITMENTS AND CONTINGENCIES (Details 2)	9 Months Ended
	Sep. 30, 2021
COMMITMENTS AND CONTINGENCIES (Note 7)
Weighted average remaining lease term (years)	4 years 6 months
Weighted average discount rate	11.40%

COMMITMENTS AND CONTINGENCIES_5

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)

Mar. 10, 2021

Sep. 06, 2016

Jun. 05, 2016

Jan. 22, 2020

Dec. 31, 2009

Sep. 30, 2021

Sep. 30, 2020

Sep. 30, 2021

Sep. 30, 2020

Dec. 31, 2020

Mar. 31, 2021

Jul. 24, 2019

Area of operating leases

12,835 square feet

Royalty percent

20

Licences

$ 1,000,000

sales

$ 4,000,000

Shares exchange

13,607,609

13,607,609

13,138,282

13,180,417

Netl loss

$ 68,000

$ 1,575,000

$ (1,626,000)

$ (2,445,000)

Accumulated deficit

141,900,000

141,900,000

Shandong Yaohua Medical Instrument Corporation [Member]

Proceeds from related party debt

233,635

Balance due for outstanding purchase order

277,000

277,000

Shares exchange

12,147

Shenghuo Medical, LLC [Member]

Payment receive descriptions

the right to receive payments equal to 2% of the Company’s future sales in the United States, up to an aggregate of $4.0 million.

Promotional Agreement [Member]

Consulting expenses

556,111

Netl loss

$ (719,000)

Accumulated deficit

$ 140,200,000

Fair vaue of warrants

$ 715,000

Description of four tranches

the Company will issue a total of 5,000,000 warrants, broken into four tranches of 1,250,000. The warrants have a strike price of $0.25 and are subject to vesting based upon the close of the Series D

Unrecognized consulting expense

158,889

Royalty Agreement [Member]

Royalty paid description

royalty initially equal to $0.10, and from and after October 2, 2016, equal to $0.20, for each disposable

Royalty consideration

$ 50,000

Mr. Blumberg [Member] | Consulting Agreement [Member]

Terms of amendment to agreement

the consulting agreement was amended to clarify that $350,000 is not intended to be debt and will not be required to be repaid in cash. Additionally, issuance of the warrants is now predicated on the Company receiving funding receipts of $1,000,000, whether from a financing, series of financing, or gross sales. The amended agreement clarified that the warrants issued to Mr. Blumberg are compensation for services, which involve obtaining financing. The Company will recognize expense for the services equal to the fair value of the warrants issued to Mr. Blumberg as the services are provided, which will coincide with the successful execution of a financing agreement over $1,000,000.

Related party liability written off

$ 350,000

$ 350,000

Gain on writing off the liability

$ 350,000

Description of exchange of subscription

(1) on September 26, 2021, 900,000 3-year warrants with an exercise price of $0.30 and 400,000 common stock shares; (2) on March 26, 2022, 900,000 3-year warrants with an exercise price of $0.40 and 400,000 common stock shares; (3) on September 26, 2022, 900,000 3-year warrants with an exercise price of $0.50 and 400,000 common stock shares; and (4) on March 26, 2023, 900,000 3-year warrants with an exercise price of $0.60 and 400,000 common stock shares.

Subscription receivable

$ 350,000

NOTES PAYABLE (Details)

NOTES PAYABLE (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Notes payable in default, including related parties	$ 0	$ 329
Dr. Cartwright
Notes payable in default, including related parties	0	1
Mr. Fowler
Notes payable in default, including related parties	0	26
Mr. Mermelstein
Notes payable in default, including related parties	0	285
GPB
Notes payable in default, including related parties	$ 0	$ 17

NOTES PAYABLE (Details 1)

NOTES PAYABLE (Details 1) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Short-term notes payable, including related parties	$ 133	$ 96
Dr. Cartwright
Short-term notes payable, including related parties	37	46
Dr. Faupel
Short-term notes payable, including related parties	0	5
Mr. Fowler
Short-term notes payable, including related parties	13	0
Premium Finance (Insurance)
Short-term notes payable, including related parties	$ 83	$ 45

NOTES PAYABLE (Details Narrativ

NOTES PAYABLE (Details Narrative) - USD ($)	Jul. 04, 2021	Jul. 04, 2020	Mar. 22, 2021	Dec. 21, 2016	Sep. 30, 2021	Dec. 31, 2019	Feb. 19, 2021	Dec. 31, 2020	Jan. 19, 2017
Short-term notes payable					$ 50,000			$ 51,000
Notes payable					$ 0			329,000
Annual interest rate description					The notes carry annual interest rates between 0% and 10% and have default rates as high as 20%.
Notes payable in default, including related parties others					$ 0			27,000,000
Promissory note payable					24,000			24,000
Accrued interest					1,380,000			2,995,000
Promissory notes issued					323,000
Mr. Fowler
Notes payable in default, including related parties others								26,000,000
Promissory note payable				$ 12,500	12,601				$ 13,900
Accrued interest									18,718
Promissory notes issued				12,500
Monthly payment of promisory notes			$ 3,580	$ 3,850
Dr. Cartwright
Annual interest rate description						The notes were initially issued with 0% interest, however interest increased to 6.0% interest
Notes payable in default, including related parties others								1,000,000
Promissory note payable							$ 267,085	1,621,000
Promissory notes issued					100,000	$ 41,000
Financing proceeds received by company						$ 1,000,000
Dr. Faupel
Annual interest rate description						The notes were initially issued with 0% interest, however interest increased to 6.0% interest
Promissory note payable							$ 153,178	$ 661,000
Promissory notes issued					85,000	$ 5,000
Financing proceeds received by company						$ 1,000,000
Premium Finance Agreement [Member]
Line of credit facility, maximum borrowing capacity	$ 109,000
Monthly payment of insurance		$ 11,299
Interest and maturity date description		interest at 4.968% and matured in April 2021
Premium Finance Agreement 1 [Member]
Line of credit facility, maximum borrowing capacity	$ 117,560
Monthly payment of insurance		$ 11,968
Interest and maturity date description		interest at 4.3% and matured in April 2022
Line of credit, balance					82,881
March 22, 2021 exchange agreement [Member] | Mr. Fowler
Monthly payment of insurance		$ 11,968			3,850
Accrued interest					18,718				$ 18,718
Short term promissory note					45,118
Short term promissory note, principal					$ 26,400

SHORTTERM CONVERTIBLE DEBT (Det

SHORTTERM CONVERTIBLE DEBT (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Convertible notes payable	$ 0	$ 1,930,000
Auctus Tranche 2 [Member]
Convertible notes payable	400,000	400,000
Auctus Prepayment Penalty [Member]
Convertible notes payable	350,000	0
Auctus Tranche 1 [Member]
Convertible notes payable	0	700,000
Total Convertible Notes Payable
Convertible notes payable	889,000	951,000
Auctus
Convertible notes payable	161,000	113,000
Debt Discount and Issuance Costs to be Amortized
Convertible notes payable	$ 22,000	$ 262,000

SHORT-TERM CONVERTIBLE DEBT (De

SHORT-TERM CONVERTIBLE DEBT (Details Narrative) - USD ($)	Jun. 05, 2016	Jun. 30, 2021	May 27, 2020	Dec. 17, 2019	Sep. 30, 2021	Dec. 31, 2020	Mar. 23, 2020	Dec. 31, 2019
Derivative liability					$ 30,000	$ 25,000
Troubled Debt Restructuring [Member]
Prepayment penalty				$ 350,000	350,000
Extinguishment of the derivative liability					700,000
Loan					84,000
Short-term Convertible Notes Payable [Member]
Convertible note issued				2,400,000
Related Party Convertible Note Payable [Member]
Distributor payment	$ 240,000
Warrant Three [Member]
Warrants issued							692,446
First Tranche [Member]
Unamortized debt issuance costs					0	31,146
Accrued interest					73,889
Fair value of warrants				745,972
Warrants issued								7,500,000
Warrant liability				635,000
Proceeds from warrant issued				635,000
Debt issuance cost				65,000
Administrative and legal expenses				570,000
Payment to convertible promissory note				89,250
Prepayment penalty				350,000	350,000	700,000
Unamortized debt discount on warrants					0	304,271
unamortized debt discount on warrants, balance					350,000	364,583
Convertible note received				$ 700,000
Rate of interest				ten percent (10%)
Description of matures				December 17, 2021
Outstanding balance of first two tranches					400,000	1,100,000
Second Tranche [Member]
Unamortized debt issuance costs					21,961	47,086
Accrued interest					54,556	24,222
unamortized debt discount on warrants, balance					432,595	377,136
Convertible note received			$ 400,000
Rate of interest			ten percent (10%)
Description of matures			December 17, 2021
Derivative liability					28,800
Auctus Fund, LLC [Member]
Default penalty		$ 112,750			48,434
Notes issued		250,000
Net proceeds		$ 100,000
Exercise price		$ 0.16
Note outstanding					161,184	112,750
Unamortized debt issuance costs					0	5,100
Accrued interest					$ 26,542	$ 10,260

CONVERTIBLE DEBT IN DEFAULT (De

CONVERTIBLE DEBT IN DEFAULT (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Convertible Notes Past Due
Convertible notes in default	$ 0	$ 1,930
Auctus
Convertible notes in default	0	40
GPB
Convertible notes in default	0	1,709
GHS [Member]
Convertible notes in default	$ 0	$ 181

CONVERTIBLE DEBT IN DEFAULT (_2

CONVERTIBLE DEBT IN DEFAULT (Details Narrative) - USD ($)	Feb. 12, 2016	May 28, 2016	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 17, 2019
Debt issuance costs			$ 86,000	$ 0
Principal amount of promissory note			$ 24,000		$ 24,000
Exchangeable shares			0
Troubled Debt Restructuring [Member]
Prepayment penalty			$ 350,000			$ 350,000
Convertible debt restructured			1,709,000
Senior Secured Promissory Note
Original issue discount	$ 287,500
Issuance of debt	1,437,500	$ 87,500
Proceeds from debt	1,029,000	$ 1,525,000
Debt issuance costs	$ 121,000
Royaltiy					35,000
Royalty payment, payable quarterly	3.85
Principal amount of promissory note					1,362,384
Convertible debt					1,709,414
Prepayment penalty					$ 347,030
Cash placement fee description					For its services, the placement agent received a cash placement fee equal to 4% of the aggregate gross proceeds from the transaction and a warrant to purchase shares of common stock equal to an aggregate of 6% of the total number of shares underlying the securities sold in the transaction,
September 2, 2020 [Member]
Repayment of debt			150,000
Forbearance amount			50,000
GHS [Member] | June 22, 2018 [Member]
Original issue discount			2,000
Convertible promissory note			$ 68,000
GPB
Series F-2 Preferred Stock issued upon conversion of debt			2,236
Exchangeable shares			7,185,000
Adusted warrant price			$ 0.20
GPB | Share-based Payment Arrangement, Tranche One [Member]
Repayment of debt			$ 450,000
GPB | Share-based Payment Arrangement, Tranche Two [Member]
Repayment of debt			100,000
GPB | Share-based Payment Arrangement, Tranche Three [Member]
Repayment of debt			$ 950,000

LONG TERM DEBT (Details)

LONG TERM DEBT (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019	Feb. 19, 2021
Bonus	$ 745,000	$ 1,094,000
Vacation	44,000	34,000
Principal amount of promissory note	24,000	24,000
Exchange for Series F-2 Preferred Stock	323,000
Dr. Faupel
Salary		134,000
Bonus		20,000
Vacation		95,000
Interest on compensation		67,000
Loans to Company		196,000
Interest on loans		149,000
Principal amount of promissory note		661,000		$ 153,178
Amount forgiven		(454,000)
Total interest accrued		29,000
Exchange for Series F-2 Preferred Stock	85,000		$ 5,000
Interest accrued	8,000
Balance outstanding, end of period	159,000	236,000
Dr. Cartwright
Salary		337,000
Bonus		675,000
Interest on compensation		528,000
Loans to Company		528,000
Interest on loans		81,000
Principal amount of promissory note		1,621,000		$ 267,085
Amount forgiven		(1,302,000)
Total interest accrued		45,000
Exchange for Series F-2 Preferred Stock	100,000		$ 41,000
Interest accrued	13,000
Balance outstanding, end of period	$ 277,000	$ 364,000

LONG TERM DEBT (Details 1)

LONG TERM DEBT (Details 1) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Total	$ 787	$ 23
Long-Term Debt - Related Parties | Mr. Fowler
2021	0
2022	30
2023	457
2024	39
2025	41
Thereafter	3
Total	$ 570

LONG TERM DEBT (Details Narrati

LONG TERM DEBT (Details Narrative) - USD ($)	May 04, 2020	May 17, 2021	Mar. 22, 2021	Feb. 19, 2021	Dec. 21, 2016	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2018	Sep. 30, 2018	Sep. 04, 2018	Jan. 19, 2017
Long-term debt-related parties						$ 579,000		$ 579,000
Accrued interest						211,000		211,000		$ 1,517,000
Debt issuance costs								86,000	$ 0
Principal amount of promissory note						24,000		24,000		24,000
Gain for extinguishment of debt						763,000	$ 20,000	578,000	(296,000)
Current portion of long-term debt						18,000		18,000		28,000
Paycheck Protection Program
Accrued interest						331		331		293
Debt forgiveness amount									23,742
Proceeds from loan	$ 50,184
Loan interest rate	1.00
Loan maturity term	24 months
Payroll costs	$ 100,000
Current portion of long-term debt						17,837		17,837		50,477
Debt interest forgiveness amount									$ 234
Dr. Cartwright
Long-term debt-related parties						271,000		271,000
Accrued interest											$ 30,000
Principal amount of promissory note				$ 267,085						1,621,000
Due to related party													$ 1,621,000
Issuance of promissory note in exchange of related party debt													319,000
Gain for extinguishment of debt											840,000
Capital contribution											432,000
Promissory note maturity date				February 18, 2023
Promissory note interest rate				6%
Debt instrument converted amount				$ 85,000
Series F-2 Preferred Stock issued upon conversion of debt				100
Debt forgiveness amount										1,302,000
Mr. Fowler
Long-term debt-related parties						150,000		150,000
Accrued interest			$ 133,590
Principal amount of promissory note					$ 12,500	12,601		12,601						$ 13,900
Due to related party			$ 546,214
Promissory note interest rate			6
Debt instrument converted amount			$ 50,000
Series F-2 Preferred Stock issued upon conversion of debt			50
Series F-2 Preferred Shares conversion description			Series F-2 Preferred Shares (convertible into 200,000 common stock shares)
Promissory note default interest rate			18
Promissory note monthly installment			$ 3,580		$ 3,850
Effective interest rate			6.18
Deferred salary			$ 412,624
Unsecured note issued upon conversion of debt			150,000
Dr. Faupel and Mr. Cartwright [Member] | July 24, 2019 [Member]
Simple interest rate									6
Debt maturity description									principal and accrued interest due in total at the date of maturity or February 18, 2023
Dr. Faupel
Long-term debt-related parties						158,000		158,000
Accrued interest											20,000
Principal amount of promissory note				$ 153,178						661,000
Due to related party												$ 661,000	661,000
Issuance of promissory note in exchange of related party debt													$ 207,000
Gain for extinguishment of debt											199,000
Capital contribution											$ 235,000
Promissory note maturity date				February 18, 2023
Promissory note interest rate				6
Debt instrument converted amount				$ 100,000
Series F-2 Preferred Stock issued upon conversion of debt				85
Debt forgiveness amount										454,000
10% Senior Unsecured Convertible Debenture
Convertible debentures right description		each debenture unit will have a right to 1,000 warrants for common stock shares, warrants have an exercise price of $0.80 and an expiration date of May 17, 2023
Change of Control premium percentage		3
Deemed price		$ 0.50
Convertible debentures		$ 1,000				1,130,000		1,130,000
Accrued interest						43,341		43,341		$ 293
Bond payable discount						266,413		266,413
Unamortized debt issuance costs						$ 76,320		76,320
Debt issuance costs								$ 787,267
Debt maturity date		May 17, 2024
Proceeds from convertible debenture		$ 1,130,000
Conversion price		$ 0.50
Long-Term Debt - Related Parties | Mr. Fowler
Accrued interest			18,718
Principal amount of promissory note			26,400
Debt forgiveness amount			$ 86,554
Debt forgiveness description			may forgive up to $259,661 if the Company complies with the repayment plan described above

INCOME (LOSS) PER COMMON SHAR_2

INCOME (LOSS) PER COMMON SHARE (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Net loss	$ (51)	$ 1,529	$ (1,922)	$ (2,520)
Basic weighted average number of shares outstanding			13,291	9,985
Net loss per share (basic)			$ (0.14)	$ (0.25)
Diluted weighted average number of shares outstanding			13,291	9,985
Net loss per share (diluted)			$ (0.14)	$ (0.25)
Dilutive equity instruments (number of equivalent units)			37,976	67,227
Warrants [Member]
Dilutive equity instruments (number of equivalent units)			16,979	8,048
Convertible Debt [Member]
Dilutive equity instruments (number of equivalent units)			908	59,179
Preferred Stock [Member]
Dilutive equity instruments (number of equivalent units)			17,837	0
Equity Option [Member]
Dilutive equity instruments (number of equivalent units)			2,252	0

INCOME (LOSS) PER COMMON SHAR_3

INCOME (LOSS) PER COMMON SHARE (Details Narrative)	9 Months Ended
	Sep. 30, 2021USD ($)
INCOME (LOSS) PER COMMON SHARE
Troubled debt restructuring	$ 972,000
Troubled debt restructuring description	the troubled debt restructuring in total would have decreased the net loss by $85,000 and causing the per share calculation to change from .14 to .15 net loss per share.